Pitney Bowes Declares Common Stock Dividend

Pitney Bowes Declares Common Stock Dividend

STAMFORD, Conn.–(BUSINESS WIRE)–
Pitney Bowes Inc. (NYSE:PBI), a global shipping and mailing company that provides technology, logistics, and financial services, today announced that its Board of Directors has declared a quarterly cash dividend on the company’s common stock of $0.05 per share. The dividend will be paid on September 8, 2022 to stockholders of record on August 22, 2022.

About Pitney Bowes

Pitney Bowes (NYSE:PBI) is a global shipping and mailing company that provides technology, logistics, and financial services to more than 90 percent of the Fortune 500. Small business, retail, enterprise, and government clients around the world rely on Pitney Bowes to remove the complexity of sending mail and parcels. For the latest news, corporate announcements and financial results, visit https://www.pitneybowes.com/us/newsroom.html. For additional information, visit Pitney Bowes at www.pitneybowes.com.

Bill Hughes

Chief Communications Officer

Pitney Bowes

203 351 6785

[email protected]

KEYWORDS: United States North America Connecticut

INDUSTRY KEYWORDS: Delivery Services Professional Services Retail Logistics/Supply Chain Management Transport Finance Other Transport

MEDIA:

Logo
Logo

Ingersoll Rand Announces Appointment of Mark Stevenson and Michael Stubblefield to Board of Directors

Ingersoll Rand Announces Appointment of Mark Stevenson and Michael Stubblefield to Board of Directors

DAVIDSON, N.C.–(BUSINESS WIRE)–
Ingersoll Rand Inc. (NYSE:IR), a global provider of mission-critical flow creation and industrial solutions, today announced that Mark Stevenson and Michael Stubblefield joined its Board of Directors on July 28, 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220802005118/en/

Mark Stevenson (Photo: Business Wire)

Mark Stevenson (Photo: Business Wire)

Mr. Stevenson is the former Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific Inc., a Fortune 100 company and world leader in serving science through its life science solutions, analytical instruments, specialty diagnostics and laboratory products and biopharma services. He held this role from 2017 until his retirement in 2022. He joined the company in 2014 as Executive Vice President and President of Life Sciences Solutions through the acquisition of Life Technologies. Mr. Stevenson previously served as President and Chief Operating Officer of Life Technologies, and President and Chief Operating Officer of Applied Biosystems prior to its merger with Invitrogen Corporation in 2008. He has an MBA from Henley Management College, United Kingdom, and a bachelor’s degree in chemistry from the University of Reading, United Kingdom.

Mr. Stubblefield currently serves as the President and Chief Executive Officer and Board member of Avantor, a Fortune 500 company and leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education and government, and advanced technologies and applied materials industries. Prior to becoming CEO of Avantor in 2014, Mr. Stubblefield served as a senior expert in the Chemicals Practice for McKinsey & Company. Before joining McKinsey, he held various leadership roles at Celanese Corporation, including Vice President and General Manager, Advanced Engineered Materials and Chief Marketing Officer. Mr. Stubblefield earned an MBA from Texas A&M University-Corpus Christi and a bachelor’s degree in chemical engineering from the University of Utah.

“I’m excited to welcome Mark and Michael to our Board,” said Ingersoll Rand Chairman of the Board of Directors and Chief Executive Officer Vicente Reynal. “We have always focused on new board members who bring experience and perspectives aligned with our key strategies. Mark and Michael are no exception. Mark’s experience in leading a growth compounder in sustainable end markets such as life sciences and medical aligns closely with our long-term vision for Ingersoll Rand, and his experience with machine learning systems supports our innovation in the areas of digitalization and IIoT. At Avantor, Michael has led a dramatic portfolio evolution since being named CEO, and has positioned the company as a leader in life sciences through new product innovation, organic growth and strategic M&A, which are three critical focus areas for us as well. Their knowledge and insights will be powerful additions as we continue on our path of becoming a growth compounder through expansion in sustainable end markets, product innovation and M&A. I look forward to their contributions.”

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to Ingersoll Rand Inc.’s (the “Company” or “Ingersoll Rand”) expectations regarding the performance of its business, its financial results, its liquidity and capital resources and other non-historical statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “forecast,” “outlook,” “target,” “endeavor,” “seek,” “predict,” “intend,” “strategy,” “plan,” “may,” “could,” “should,” “will,” “would,” “will be,” “on track to” “will continue,” “will likely result,” “guidance” or the negative thereof or variations thereon or similar terminology generally intended to identify forward-looking statements. All statements other than historical facts are forward-looking statements. These forward-looking statements are based on Ingersoll Rand’s current expectations and are subject to risks and uncertainties, which may cause actual results to differ materially from these current expectations. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. The inclusion of such statements should not be regarded as a representation that such plans, estimates or expectations will be achieved. Important factors that could cause actual results to differ materially from such plans, estimates or expectations include, among others, (1) the impact on the Company’s business, suppliers and customers and global economic conditions of the COVID-19 pandemic, including business disruptions caused by government restrictions; (2) unexpected costs, charges or expenses resulting from the completed and proposed business combinations; (3) uncertainty of the expected financial performance of the Company; (4) failure to realize the anticipated benefits of the completed and proposed business combinations; (5) the ability of the Company to implement its business strategy; (6) difficulties and delays in achieving revenue and cost synergies; (7) inability of the Company to retain and hire key personnel; (8) evolving legal, regulatory and tax regimes; (9) changes in general economic and/or industry specific conditions; (10) actions by third parties, including government agencies; (11) adverse impact on our operations and financial performance due to natural disaster, catastrophe, pandemic, geopolitical tensions or other events outside of our control; and (12) other risk factors detailed in Ingersoll Rand’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), as such factors may be updated from time to time in its periodic filings with the SEC, which are available on the SEC’s website at http://www.sec.gov. The foregoing list of important factors is not exclusive. Any forward-looking statements speak only as of the date of this release. Ingersoll Rand undertakes no obligation to update any forward-looking statements, whether as a result of new information or development, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

About Ingersoll Rand Inc.

Ingersoll Rand Inc. (NYSE:IR), driven by an entrepreneurial spirit and ownership mindset, is dedicated to helping make life better for our employees, customers and communities. Customers lean on us for our technology-driven excellence in mission-critical flow creation and industrial solutions across 40+ respected brands where our products and services excel in the most complex and harsh conditions. Our employees develop customers for life through their daily commitment to expertise, productivity and efficiency. For more information, visit www.IRCO.com.

Investor Contact:

Matthew Fort

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Manufacturing Machinery Engineering Machine Tools, Metalworking & Metallurgy Chemicals/Plastics

MEDIA:

Logo
Logo
Photo
Photo
Mark Stevenson (Photo: Business Wire)
Photo
Photo
Michael Stubblefield (Photo: Business Wire)

CenterPoint Energy Reports Strong Second Quarter Results and Raises Full Year Earnings Guidance

CenterPoint Energy Reports Strong Second Quarter Results and Raises Full Year Earnings Guidance

  • Reported Q2 2022 earnings of $0.28 and $0.31 per diluted share on a GAAP and non-GAAP basis, respectively
  • Full year 2022 non-GAAP EPS guidance increased to $1.37-$1.39, representing an increase of 9% at the midpoint compared to full year 2021
  • From this higher $1.37-$1.39 guidance, CNP is reaffirming industry leading non-GAAP EPS growth of 8% annually for 2023 and 2024 and mid to high-end of the 6-8% annually range from 2025 through 2030
  • Capital spending on track for year with ~$2 billion invested as of the end of Q2 for the benefit of customers
  • Continued 30-year trend of at least 2% average annual customer growth in Houston area supporting customer affordability

HOUSTON–(BUSINESS WIRE)–
CenterPoint Energy, Inc. (NYSE: CNP) or “CenterPoint” today reported income available to common shareholders of $179 million, or $0.28 per diluted share on a GAAP basis, for the second quarter of 2022 compared to $0.37 of diluted earnings per share, including $0.09 of midstream for the second quarter of 2021.

On a non-GAAP basis, EPS for the second quarter was $0.31, an 11% increase to the comparable quarter in 2021. The positive variance was primarily driven by favorable weather, usage and continued organic growth across the Houston Electric service territory, which represented an increase of approximately $0.03 per share over second quarter of 2021.

“The full year 2022 guidance raise is driven by the increased confidence around our business performance, primarily driven by the performance of our Houston Electric business. This is the fifth time we have increased our guidance under this management team. We are now on track to meet $1.37-$1.39 non-GAAP EPS guidance for the full year 2022, a 9% increase over 2021, setting a new and higher baseline for future earnings growth,” said Dave Lesar, President and Chief Executive Officer of CenterPoint.

“We are in year two of our ten-year, $40 billion-plus capital plan and have invested nearly 50% of our 2022 investment plan as of the second quarter. We expect to be in a position to update our investment plan on our third quarter earnings call, focused on incremental customer driven capital opportunities to continue our investment in the resiliency, safety, and growth across our system. We are committed to executing this plan with a continued focus on customer affordability,” continued Lesar.

Lesar added, “We remain steadfast on delivering on our premium value proposition quarter after quarter, underpinned by our pure play regulated utility model, to the benefit of our customers, investors and other stakeholders.”

Earnings Outlook

Given the merger between Enable and Energy Transfer and CenterPoint’s divestiture of its remaining midstream investments during 2022, CenterPoint will be presenting a consolidated non-GAAP EPS guidance range for 2022, which is the comparable measure to non-GAAP Utility EPS reported in 2021.

In addition to presenting its financial results in accordance with GAAP, including presentation of income (loss) available to common shareholders and diluted earnings (loss) per share, CenterPoint provides guidance based on non-GAAP income and non-GAAP diluted earnings per share. Generally, a non-GAAP financial measure is a numerical measure of a company’s historical or future financial performance that excludes or includes amounts that are not normally excluded or included in the most directly comparable GAAP financial measure.

Management evaluates CenterPoint’s financial performance in part based on non-GAAP income and non-GAAP earnings per share. Management believes that presenting these non-GAAP financial measures enhances an investor’s understanding of CenterPoint’s overall financial performance by providing them with an additional meaningful and relevant comparison of current and anticipated future results across periods. The adjustments made in these non-GAAP financial measures exclude items that management believes do not most accurately reflect the company’s fundamental business performance. These excluded items are reflected in the reconciliation tables of this news release, where applicable. CenterPoint’s non-GAAP income and non-GAAP diluted earnings per share measures should be considered as a supplement to, and not as a substitute for, or superior to, income available to common shareholders and diluted earnings per share, which respectively are the most directly comparable GAAP financial measures. These non-GAAP financial measures also may be different than non-GAAP financial measures used by other companies.

2021 non-GAAP Utility EPS

“Utility EPS” (a non-GAAP financial measure) included net income from the company’s Electric and Natural Gas segments, as well as after-tax Corporate and Other operating income and an allocation of corporate overhead based upon Electric’s and Natural Gas’s relative earnings contribution. Corporate overhead consisted primarily of interest expense, preferred stock dividend requirements, and other items directly attributable to the parent along with the associated income taxes.

  • 2021 Utility EPS excluded:

    • Earnings or losses from the change in value of the CenterPoint 2.0% Zero-Premium Exchangeable Subordinated Notes due 2029 (“ZENS”) and related securities
    • Earnings and losses associated with the ownership and disposal of midstream common and preferred units (including amounts reported in discontinued operations), net gain associated with the consummation of the merger between Enable Midstream Partners, LP and Energy Transfer LP, a corresponding amount of debt related to midstream common and preferred units, and an allocation of associated corporate overhead
    • Cost associated with the early extinguishment of debt
    • Impacts associated with Arkansas and Oklahoma gas LDC sales
    • Certain impacts associated with other mergers and divestitures

2022 non-GAAP EPS guidance range

Beginning in 2022, CenterPoint no longer separates utility and midstream operations and will report on a consolidated non-GAAP EPS basis.

  • 2022 non-GAAP EPS guidance excludes:

    • Earnings or losses from the change in value of ZENS and related securities
    • Gain and impact, including related expenses, associated with mergers and divestitures, primarily the Arkansas and Oklahoma gas LDC sales
    • Income and expense related to ownership and disposal of Energy Transfer common and Series G preferred units, and a corresponding amount of debt related to the units

In providing 2022 non-GAAP EPS guidance, CenterPoint does not consider the items noted above and other potential impacts such as changes in accounting standards, impairments, or other unusual items, which could have a material impact on GAAP reported results for the applicable guidance period. The 2022 non-GAAP EPS guidance range also considers assumptions for certain significant variables that may impact earnings, such as customer growth and usage including normal weather, throughput, recovery of capital invested, effective tax rates, financing activities and related interest rates, and regulatory and judicial proceedings. To the extent actual results deviate from these assumptions, the 2022 non-GAAP EPS guidance range may not be met, or the projected annual non-GAAP EPS growth rate may change. CenterPoint is unable to present a quantitative reconciliation of forward-looking non-GAAP diluted earnings per share because changes in the value of ZENS and related securities, future impairments, and other unusual items are not estimable and are difficult to predict due to various factors outside of management’s control.

Reconciliation of Consolidated income (loss) available to common shareholders and diluted earnings (loss) per share (GAAP) to non-GAAP income and non-GAAP diluted earnings per share

 

Quarter Ended

June 30, 2022

 

Dollars in

millions

Diluted EPS (1)

Consolidated income (loss) available to common shareholders and diluted EPS

$

179

 

$

0.28

 

 

 

 

 

 

ZENS-related mark-to-market (gains) losses:

 

 

 

 

Equity securities (net of taxes of $22) (2)(3)

 

49

 

 

0.08

 

Indexed debt securities (net of taxes of $22) (2)

 

(52

)

 

(0.08

)

 

 

 

 

 

Midstream-related earnings (net of taxes of $10) (2)(4)

 

(1

)

 

 

 

 

 

 

 

Impacts associated with gas LDC sales (net of taxes of $112) (2)

 

19

 

 

0.03

 

 

 

 

 

 

Consolidated Income on a non-GAAP basis

$

194

 

$

0.31

 

1)

Quarterly diluted EPS on both a GAAP and non-GAAP basis are based on the weighted average number of shares of common stock outstanding during the quarter, and the sum of the quarters may not equal year-to-date diluted EPS

2)

Taxes are computed based on the impact removing such item would have on tax expense. Taxes related to the gas LDC sales, and the midstream-related earnings are booked proportionately by applying the projected annual effective tax rate percentage to income earned each quarter in accordance with GAAP. Additional tax expense related primarily to the write-off of non-deductible goodwill will be reflected in tax expense over the remainder of 2022 and excluded from non-GAAP EPS

3)

Comprised of common stock of AT&T Inc., Charter Communications, Inc. and Warner Brothers Discovery, Inc.

4)

Includes earnings and expenses related to ownership and disposal of Energy Transfer units, a corresponding amount of debt related to the units and an allocation of associated corporate overhead.

Reconciliation of Consolidated income (loss) available to common shareholders and diluted earnings (loss) per share (GAAP) to non-GAAP income and non-GAAP diluted earnings per share

Quarter ended

June 30, 2021

 

Utility Operations

 

Midstream Investments

 

Corporate and Other (4)

 

Consolidated

 

Dollars in millions

Diluted EPS (1)

 

Dollars in millions

Diluted EPS (1)

 

Dollars in millions

Diluted EPS (1)

 

Dollars in millions

Diluted EPS (1)

Consolidated income (loss) available to common shareholders and diluted EPS(1)

$

199

 

 

$

0.33

 

 

 

$

51

 

 

$

0.09

 

 

 

$

(29

)

 

$

(0.05

)

 

 

$

221

 

 

$

0.37

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ZENS-related mark-to-market (gains) losses:

 

 

 

 

 

 

 

 

 

 

 

Marketable securities (net of taxes of $15)(2)(3)

 

 

 

 

 

 

 

 

 

 

(60

)

 

(0.10

)

 

 

(60

)

 

(0.10

)

 

Indexed debt securities (net of taxes of $15)(3)

 

 

 

 

 

 

 

 

 

 

62

 

 

0.10

 

 

 

62

 

 

0.10

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Impacts associated with the Vectren merger (net of taxes of $0)(2)

2

 

 

0.01

 

 

 

 

 

 

 

 

 

 

 

 

 

2

 

 

0.01

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Impacts associated with gas LDC sales(2)

(11

)

(0.02

)

 

 

 

(6

)

(0.01

)

(17

)

(0.03

)

 

Cost associated with the early extinguishment of debt (net of taxes of $1)(2)

 

 

 

 

 

 

 

 

 

 

6

 

 

0.01

 

 

 

6

 

 

0.01

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate and Other Allocation

(25

)

 

(0.04

)

 

 

(2

)

 

(0.01

)

 

 

30

 

 

0.05

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated on a non-GAAP basis

$

165

 

 

$

0.28

 

 

 

$

49

 

 

$

0.08

 

 

 

$

 

 

$

 

 

 

$

214

 

 

$

0.36

 

 

 

(1) Quarterly diluted EPS on both a GAAP and non-GAAP basis are based on the weighted average number of shares of common stock outstanding during the quarter, and the sum of the quarters may not equal year-to-date diluted EPS. EPS figures for Utility Operations, Corporate and Other and Discontinued Operations are non-GAAP financial measures

(2) Taxes are computed based on the impact removing such item would have on tax expense

(3) Comprised of common stock of AT&T Inc. and Charter Communications

(4) Corporate and Other, plus income allocated to preferred shareholders.

Filing of Form 10-Q for CenterPoint Energy, Inc.

Today, CenterPoint Energy, Inc. filed with the Securities and Exchange Commission (SEC) its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. A copy of that report is available on the company’s website, under the Investors section. Investors and others should note that we may announce material information using SEC filings, press releases, public conference calls, webcasts, and the Investor Relations page of our website. In the future, we will continue to use these channels to distribute material information about the company and to communicate important information about the company, key personnel, corporate initiatives, regulatory updates and other matters. Information that we post on our website could be deemed material; therefore, we encourage investors, the media, our customers, business partners and others interested in our company to review the information we post on our website.

Webcast of Earnings Conference Call

CenterPoint’s management will host an earnings conference call on August 2, 2022, at 7:00 a.m. Central time / 8:00 a.m. Eastern time. Interested parties may listen to a live audio broadcast of the conference call on the company’s website under the Investors section. A replay of the call can be accessed approximately two hours after the completion of the call and will be archived on the website for at least one year.

About CenterPoint Energy, Inc.

As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more than 7 million metered customers in Indiana, Louisiana, Minnesota, Mississippi, Ohio and Texas. As of June 30, 2022, the company owned approximately $35 billion in assets. With approximately 8,900 employees, CenterPoint Energy and its predecessor companies have been in business for more than 150 years. For more information, visit CenterPointEnergy.com.

Forward-looking Statements

This news release includes, and the earnings conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this news release, the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “objective,” “plan,” “potential,” “predict,” “projection,” “should,” “target,” “will” or other similar words are intended to identify forward-looking statements. These forward-looking statements are based upon assumptions of management which are believed to be reasonable at the time made and are subject to significant risks and uncertainties. Actual events and results may differ materially from those expressed or implied by these forward-looking statements. Examples of forward-looking statements in this news release or on the earnings conference call include statements regarding capital investments (including with respect to expected updates to our 10-year capital plan, renewables projects, mobile generation spend and the City of Houston’s Master Energy Plan and Resilient Now), the impacts of the February 2021 winter storm event on our business and service territories, the recovery and timing of recovery of associated gas costs and related litigation, future earnings and guidance, including long-term growth rate, operations and maintenance expense reductions, financing plans (including the timing of any future equity issuances, securitization, credit metrics and parent level debt), the impact of disruptions to the global supply chain on our business, including our generation transition plan, ZENS and impacts of the maturity of ZENS, tax planning opportunities (such as any potential use of the repairs expense deduction), future financial performance and results of operations, including with respect to regulatory actions and recoverability of capital investments, customer rate affordability, value creation, opportunities and expectations, ESG strategy, including transition to Net Zero, and any other statements that are not historical facts are forward-looking statements. Each forward-looking statement contained in this news release or discussed on the earnings conference call speaks only as of the date of this release or the earnings conference call.

Important factors that could cause actual results to differ materially from those indicated by the provided forward-looking information include, but are not limited to, risks and uncertainties relating to: (1) CenterPoint’s business strategies and strategic initiatives, restructurings, joint ventures and acquisitions or dispositions of assets or businesses, including the completed sale of our Natural Gas businesses in Arkansas and Oklahoma, the exit from midstream and the internal restructuring of certain subsidiaries, which we cannot assure you will have the anticipated benefits to us; (2) industrial, commercial and residential growth in CenterPoint’s service territories and changes in market demand; (3) CenterPoint’s ability to fund and invest planned capital, and the timely recovery of its investments; (4) financial market and general economic conditions, including access to debt and equity capital and the effect on sales, prices and costs; (5) continued disruptions to the global supply chain and increases in commodity prices; (6) actions by credit rating agencies, including any potential downgrades to credit ratings; (7) the timing and impact of regulatory proceedings and actions and legal proceedings, including those related to Houston Electric’s mobile generation and the February 2021 winter storm event; (8) legislative decisions, including tax and developments related to the environment such as global climate change, air emissions, carbon, waste water discharges and the handling of coal combustion residuals, among others, and CenterPoint’s Net Zero and carbon emissions reduction goals; (9) the impact of the COVID-19 pandemic; (10) the recording of impairment charges; (11) weather variations and CenterPoint’s ability to mitigate weather impacts, including impacts from the February 2021 winter storm event; (12) changes in business plans; (13) CenterPoint’s ability to execute on its initiatives, targets and goals, including its Net Zero and carbon emissions reduction goals and operations and maintenance goals; and (14) other factors discussed CenterPoint’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and CenterPoint’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022, including in the “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” sections of such reports, and other reports CenterPoint or its subsidiaries may file from time to time with the Securities and Exchange Commission.

Media:

Communications

[email protected]

Investors:

Jackie Richert / Ben Vallejo

713.207.6500

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Energy Utilities Oil/Gas

MEDIA:

Logo
Logo

Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress

Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress

Rolling NDA submission for zuranolone in MDD and PPD remains on track, with completion expected in the second half of 2022

Announced positive topline data from the Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD

Enrolling multiple Phase 2 studies across neuropsychiatry and neurology franchises, additional trials expected to initiate throughout 2022

Cash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, expected to support operations into 2025

Conference call today at 8:00 a.m. ET

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the second quarter ended June 30, 2022.

“The first half of 2022 has been marked by important clinical and regulatory achievements across our entire pipeline, paving the way for continued focused execution throughout the remainder of the year,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “We are making progress on the NDA submission for zuranolone and building our organization to support a potential launch. Based on the consistent clinical profile of zuranolone, we believe it has the potential, if approved, to address the significant unmet need for people suffering from MDD and PPD and we are working with a sense of urgency toward our goal of bringing zuranolone to them. Beyond zuranolone, we are continuing to advance our pipeline, with the presentation of multiple data sets at key upcoming scientific congresses. I believe our progress this year, combined with the strong foundation we’ve built, supports our growth as a leader in brain health and a top-tier biopharmaceutical company.”

Second Quarter 2022 Portfolio Updates

Sage is advancing a portfolio of clinical programs featuring internally discovered novel chemical entities with the potential to become differentiated products designed to improve brain health by targeting the GABAA and NMDA receptor systems. Dysfunction in these systems is thought to be at the core of numerous neurological and neuropsychiatric disorders.

Depression Franchise

Sage’s depression franchise features zuranolone, Sage’s next-generation positive allosteric modulator (PAM) of GABAAreceptors being evaluated in clinical development as a treatment for various affective disorders, and ZULRESSO® (brexanolone) CIV injection, approved by the U.S. Food and Drug Association (FDA) as the first treatment specifically indicated for postpartum depression (PPD). Zuranolone has received Breakthrough Therapy and Fast Track Designation for the treatment ofmajor depressive disorder (MDD) and Fast Track Designation for the treatment of PPD from the FDA.

Zuranolone is being evaluated as a potential rapid-acting, once-daily, oral two-week treatment for MDD and PPD in the LANDSCAPE and NEST clinical development programs, respectively. Across seven positive clinical trials, zuranolone has demonstrated rapid and sustained relief of depressive symptoms in people with MDD and PPD. In the second quarter of this year, Sage and its collaborator, Biogen, announced that the SKYLARK Study of zuranolone in PPD met its primary and all key secondary endpoints.

In June 2022, Sage and Biogen announced that the rolling NDA submission that was previously initiated will seek approval for both MDD and PPD in one filing. The Companies plan to complete submission of the single NDA for zuranolone for the treatment of both MDD and PPD to the FDA in the second half of this year, accelerating previously planned timelines for PPD.

The Company also shared insights from the terminated RAINFOREST and REDWOOD Studies today. The RAINFOREST Study was designed to investigate the efficacy and safety of 30 mg zuranolone in comorbid MDD and insomnia. The REDWOOD Study was designed to study fixed schedule intermittent dosing of 30 mg zuranolone throughout the course of a year. Both studies were terminated in 2020 based on the Company’s plans to advance the program with the 50 mg dose of zuranolone.

The RAINFOREST Study, which enrolled 87 patients, was terminated prior to achieving the planned sample size. As the study was not fully enrolled, the statistical analysis plan was invalid. The study directionality showed that zuranolone may benefit sleep efficiency, with numerical improvement in objective measures of quality of sleep, including wake after sleep onset, total sleep time, latency to persistent sleep, median number of awakenings, and mean duration of awakenings, and differences on endpoints involving REM sleep. The REDWOOD Study did not enroll enough patients for efficacy analyses to be performed. There were no new safety findings from the study. In the open-label SHORELINE Study, a large naturalistic study in the zuranolone development program, 80% of patients who responded to initial treatment with zuranolone 50 mg received only 1 or 2 treatment courses during their time in the year-long study, with a median time to the second treatment course of 249 days also with no new safety findings.

Additionally, Sage today announced that the SUNBIRD Study evaluating the safe-use administration of ZULRESSO as a treatment for PPD in a woman’s home has completed enrollment. Sage does not plan any label changes from this study.

The Company expects to achieve the following milestones across its depression franchise in 2022:

  • Late 2022:
    • Complete NDA submission for zuranolone in MDD and PPD (2H 2022).
    • Present additional zuranolone data throughout 2022.

Neuropsychiatry Franchise

Sage’s neuropsychiatry franchise features SAGE-718, the Company’s first-in-class NMDA receptor PAM and lead neuropsychiatric drug candidate, in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, potentially including Huntington’s disease (HD), Parkinson’s disease (PD) and Alzheimer’s disease (AD). SAGE-718 received Fast Track Designation from the FDA for development as a potential treatment for HD.

Sage is advancing a robust clinical program for SAGE-718 with multiple ongoing or planned Phase 2 studies, including the DIMENSION and SURVEYOR Studies in people with HD cognitive impairment, the lead indication for SAGE-718, the PRECEDENT Study in people with mild cognitive impairment (MCI) associated with PD and a Phase 2 study in people with MCI and mild dementia due to AD.

  • DIMENSION (CIH-201) Study: Sage is currently enrolling the Phase 2 DIMENSION Study, a double-blind, placebo-controlled study in people with HD cognitive impairment. The study is designed to evaluate the efficacy of once-daily dosed SAGE-718 over three months, with a target enrollment of approximately 178 people. Sage expects the DIMENSION Study to include more than 40 clinical sites.
  • SURVEYOR (CIH-202) Study: The SURVEYOR Study is a placebo-controlled Phase 2 study in people with HD cognitive impairment and healthy volunteers, with the goal of generating evidence linking efficacy signals on cognitive performance to domains of real-world functioning.
  • PRECEDENT (CNP-202) Study: The Phase 2 PRECEDENT Study is a double-blind, placebo-controlled study in people with MCI due to PD. The study is designed to evaluate the safety and efficacy of SAGE-718 in people with MCI due to PD over 42 days, followed by a controlled follow-up period.

The Company expects to achieve the following milestones across its neuropsychiatry franchise in 2022:

  • Late 2022:
    • Phase 3 Study in HD (CIH-301): Initiate a Phase 3 safety study of SAGE-718 in people with HD cognitive impairment.
    • Phase 2 Study in AD (CNA-202): Initiate a placebo-controlled Phase 2 study of SAGE-718 in people with mild cognitive impairment and mild dementia due to AD.
    • Present additional SAGE-718 data throughout 2022.

Neurology Franchise

Sage’s neurology franchise features SAGE-324 and SAGE-689. SAGE-324, a next-generation PAM of GABAA receptors and Sage’s lead neurology program, is in development as a potential oral therapy for neurological conditions, such as essential tremor (ET), epilepsy and PD. SAGE-689 is an intramuscular GABAA receptor PAM in development as a potential therapy for disorders associated with acute GABA hypofunction.

Sage and its collaborator, Biogen, are currently enrolling people in the Phase 2b KINETIC 2 placebo-controlled study of SAGE-324 in ET following positive results from the KINETIC Study. The KINETIC 2 Study is a Phase 2b dose-ranging study with the primary goal of defining the dose and frequency for SAGE-324 in ET with a good tolerability profile and a dosing schedule to maintain plasma concentrations needed for sustained tremor symptom control in treating ET.

Sage also recently initiated a Phase 2 long-term open label safety study with SAGE-324, designed to evaluate the long-term safety and tolerability of SAGE-324 in ET, with incidence of treatment-emergent adverse events as the primary endpoint.

SAGE-689 continues in Phase 1 development.

The Company expects to achieve the following milestones across its neurology franchise in 2022:

  • Late 2022:
    • Complete enrollment in KINETIC 2 Study of SAGE-324 in ET.
    • Present additional SAGE-324 data throughout 2022.

Early Development

Sage is progressing its early development programs with IND-enabling work underway for SAGE-319 and SAGE-421.

  • SAGE-319: an oral, extrasynaptic GABAA receptor preferring PAM that Sage plans to study for potential use in disorders of social interaction.
  • SAGE-421: an oral, NMDA receptor PAM that Sage plans to study for potential use in neurodevelopmental disorders and cognitive recovery and rehabilitation.

FINANCIAL RESULTS FOR THE SECOND QUARTER 2022

  • Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2022 were $1.5 billion compared to $1.6 billion at March 31, 2022.
  • Revenue: Net revenue from sales of ZULRESSO was $1.5 million in the second quarter of 2022, compared to $1.6 million in the same period of 2021.
  • R&D Expenses: Research and development expenses were $77.3 million, including $6.5 million of non-cash stock-based compensation expense, in the second quarter of 2022 compared to $66.2 million, including $13.5 million of non-cash stock-based compensation expense, for the same period in 2021. The increase in R&D expenses was primarily due to increased spending on SAGE-324 and Sage’s wholly owned pipeline, including SAGE-718 and other programs. The reimbursement from Biogen pursuant to the Sage/Biogen Collaboration and License Agreement was $21.0 million in the second quarter of 2022 compared to $20.1 million in the same period of 2021.
  • SG&A Expenses: Selling, general and administrative expenses were $52.4 million, including $8.2 million of non-cash stock-based compensation expense, in the second quarter of 2022, compared to $43.3 million, including $14.2 million of non-cash stock-based compensation expense, for the same period in 2021. The increase in SG&A expenses was primarily due to hiring employees to support ongoing activities in anticipation of potential future product launches of our product candidates. The reimbursement from Biogen pursuant to the Sage/Biogen Collaboration and License Agreement was $2.8 million in the second quarter of 2022 compared to $3.5 million in the same period of 2021.
  • Net Loss: Net loss was $126.3 million for the second quarter of 2022 compared to $107.2 million for the same period of 2021.

FINANCIAL GUIDANCE

  • Sage anticipates cash, cash equivalents and marketable securities of approximately $1.3 billion at the end of 2022.
  • The Company does not anticipate receipt of any milestone payments from collaborations in 2022.
  • The Company anticipates R&D and SG&A spending to increase as it advances planned and ongoing studies for SAGE-718 and SAGE-324 and prepares for the potential launch of zuranolone.
  • The Company believes its cash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, will support its operations into 2025.

Conference Call Information

Sage will host a conference call and webcast today, Tuesday, August 2, at 8:00 a.m. ET to discuss its second quarter 2022 financial results and recent corporate updates. The live webcast can be accessed on the investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available on Sage’s website approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company fearlessly leading the way to create a world with better brain health. Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. For more information, please visit. www.sagerx.com.

Forward-Looking Statements

Various statements in this release concern Sage’s future expectations, plans and prospects, including without limitation our statements regarding: plans and potential timing for completion of our rolling NDA submission for zuranolone in MDD and PPD; our belief in the regulatory filing pathway for zuranolone in MDD and PPD; the potential profile and benefit of zuranolone in MDD and PPD; the potential for regulatory approval and commencement of commercialization of zuranolone; other planned next steps for the zuranolone program; anticipated timelines for commencement of trials, initiation of new activities and other plans for our other programs and early stage pipeline; our belief in the potential profile and benefit of our product candidates; potential indications for our product candidates; the potential for success of our programs, and the opportunity to help patients in various indications; the mission and goals for our business; and our expectations with respect to 2022 year-end cash, no receipt of milestones from collaborations in 2022, funding of future operations and expectations for increases in expenses. These statements constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: we may experience delays or unexpected hurdles in our efforts to complete our rolling NDA submission for zuranolone in MDD and PPD and we may not be able to complete the submission on the timeline we expect or at all; the FDA may find inadequacies and deficiencies in our NDA for zuranolone, including in the data we submit, despite prior discussions, and may decide not to accept the NDA for filing; even if the FDA accepts the NDA for filing, the FDA may find that the data included in the NDA are not sufficient for approval and may not approve the NDA; the FDA may decide that the design, conduct or results of our completed and ongoing clinical trials for zuranolone, even if positive, are not sufficient for approval in MDD or PPD and may require additional trials or data which may significantly delay and put at risk our efforts to obtain approval and may not be successful; even if our NDA is successfully filed and accepted, the FDA may not meet expected review timelines for our NDA; other decisions or actions of the FDA or other regulatory agencies may affect our efforts with respect to zuranolone and our plans, progress or results; results of ongoing or future studies may impact our ability to obtain approval of zuranolone or impair the potential profile of zuranolone; success in earlier clinical trials of any of our product candidates may not be repeated or observed in ongoing or future studies, and ongoing and future clinical trials may not meet their primary or key secondary endpoints which may substantially impair development; unexpected concerns may arise from additional data, analysis or results from any of our completed studies; we may encounter adverse events at any stage that negatively impact further development, the potential for approval or the potential for successful commercialization or that require additional nonclinical and clinical work which may not yield positive results; we may encounter delays in initiation, conduct or completion of our ongoing and planned clinical trials, including as a result of slower than expected site initiation or enrollment, the need or decision to expand the trials or other changes, that may impact our ability to meet our expected timelines and increase our costs; decisions or actions of the FDA or other regulatory agencies may affect the initiation, timing, design, size, progress and cost of clinical trials and our ability to proceed with further development or may impair the potential for successful development; the anticipated benefits of our ongoing collaborations, including the achievement of events tied to milestone payments or the successful development or commercialization of products and generation of revenue, may never be achieved; the need to align with our collaborators may hamper or delay our development and commercialization efforts or increase our costs; our business may be adversely affected and our costs may increase if any of our key collaborators fails to perform its obligations or terminates our collaboration; the internal and external costs required for our ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected which may cause us to use cash more quickly than we expect or change or curtail some of our plans or both; we may never be able to generate meaningful revenues from sales of ZULRESSO or to generate revenues at levels we expect or at levels necessary to justify our investment; we may not be successful in our efforts to gain regulatory approval of products beyond ZULRESSO and, even if successfully developed and approved, we may not achieve revenues from such products at the levels we expect; our expectations as to year-end cash and sufficiency of cash to fund future operations and expense levels may prove not to be correct for these and other reasons such as changes in plans or actual events being different than our assumptions; we may be opportunistic in our future financing plans even if available cash is sufficient; additional funding may not be available on acceptable terms when we need it; the number of patients with the diseases or disorders for which our products are developed, the unmet need for additional treatment options and the potential market for our current or future products may be significantly smaller than we expect; any of our products that may be approved in the future may not achieve market acceptance or we may encounter reimbursement-related or other market-related issues that impact the success of our commercialization efforts; and we may encounter technical and other unexpected hurdles in the development and manufacture of our product candidates or the commercialization of our marketed product which may delay our timing or change our plans, increase our costs or otherwise negatively impact our business; as well as those risks more fully discussed in the section entitled “Risk Factors” in our most recent quarterly report, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today, and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

Financial Tables

             
Sage Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)
             
 

Three Months Ended June 30,

   

Six Months Ended June 30,

 

 

2022

 

 

2021

 

   

 

2022

 

 

2021

 

Product revenue, net

 $

                1,501

 

 $

                 1,643

 

   

 $

           3,082

 

 $

                 3,226

             
Operating costs and expenses:            
Cost of goods sold

 

                      200

 

 

                      148

 

   

 

                 486

 

 

                      335

 

Research and development

 

                 77,297

 

 

                  66,170

 

   

 

          155,315

 

 

                124,226

 

Selling, general and administrative

 

                 52,411

 

 

                  43,346

 

   

 

            98,888

 

 

                  83,193

 

Total operating costs and expenses

 

               129,908

 

 

                109,664

 

   

 

          254,689

 

 

                207,754

Loss from operations

 

              (128,407

)

 

              (108,021

)

   

 

         (251,607

)

 

              (204,528

)

             
Interest income, net

 

                   2,102

 

 

                      732

 

   

 

              3,270

 

 

                   1,440

 

Other income, net

 

                       45

 

 

                        44

 

   

 

                   22

 

 

                        79

 

Net loss

 $

           (126,260

)

 $

            (107,245

)

   

 $

      (248,315

)

 $

            (203,009

)

Net loss per share – basic and diluted

 $

                (2.13

)

 $

                 (1.83

)

   

 $

            (4.20

)

 $

                 (3.47

)

Weighted average shares outstanding – basic and diluted

 

           59,266,322

 

 

           58,582,569

 

   

 

      59,148,246

 

 

           58,478,970

 

 
 
Sage Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets 
(in thousands)
(unaudited)
       
  June 30,
2022
  December 31,
2021
Cash, cash equivalents and marketable securities

 $

          1,513,707

 

 $

          1,742,296

Total assets

 $

          1,601,377

 

 $

          1,825,288

Total liabilities

 $

              97,141

 

 $

               96,257

Total stockholders’ equity

 $

          1,504,236

 

 $

          1,729,031

ZULRESSO (brexanolone) SELECT IMPORTANT SAFETY INFORMATION

This does not include all the information needed to use ZULRESSO safely and effectively. See full prescribing information for ZULRESSO.

WARNING: EXCESSIVE SEDATION AND SUDDEN LOSS OF CONSCIOUSNESS

See full prescribing information for complete boxed warning

Patients are at risk of excessive sedation or sudden loss of consciousness during administration of ZULRESSO.

Because of the risk of serious harm, patients must be monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. Patients must be accompanied during interactions with their child(ren).

ZULRESSO is available only through a restricted program called the ZULRESSO REMS.

WARNINGS AND PRECAUTIONS

Suicidal Thoughts and Behaviors: Consider changing the therapeutic regimen, including discontinuing ZULRESSO, in patients whose PPD becomes worse or who experience emergent suicidal thoughts and behavior.

ADVERSE REACTIONS: Most common adverse reactions (incidence ≥5% and at least twice the rate of placebo) were sedation/somnolence, dry mouth, loss of consciousness, and flushing/hot flush.

USE IN SPECIFIC POPULATIONS

Pregnancy: ZULRESSO may cause fetal harm. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at https://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/antidepressants/

Renal Impairment: Avoid use of ZULRESSO in patients with end stage renal disease (ESRD)

Controlled Substance: ZULRESSO contains brexanolone, a Schedule IV controlled substance under the Controlled Substances Act.

To report SUSPECTED ADVERSE REACTIONS, contact Sage Therapeutics, Inc. at 1-844-4-SAGERX (1-844-472-4379) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Prescribing Information including Boxed Warning.

Investors

Helen Rubinstein

315-382-3979

[email protected]

Media

Becky Kern

914-772-2310

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Mental Health Health Clinical Trials General Health Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Sprott Launches First ESG Gold ETF (“SESG”)

Key Partners Include Agnico Eagle Mines and Yamana Gold

TORONTO, Aug. 02, 2022 (GLOBE NEWSWIRE) — Sprott Asset Management LP (“Sprott”), a wholly-owned subsidiary of Sprott Inc. (NYSE/TSX: SII), today announced the launch of the Sprott ESG Gold ETF (NYSE Arca: SESG) (“SESG”), the world’s first ETF to exclusively source and refine gold from globally recognized mining leaders in ESG based on special criteria developed by Sprott. The new ETF will begin trading on the New York Stock Exchange Arca on August 2, 2022.

SESG is the first gold ETF that invests in gold bullion that meets the environmental, social, and governance (“ESG”) and provenance standards specially developed by Sprott. Sprott has partnered with the Royal Canadian Mint (“RCM”) to provide investors with an ETF that only sources gold from companies and mines that meet Sprott’s ESG screening criteria. Initially, Sprott ESG Approved Gold will be sourced from several Canadian mines operated by Agnico Eagle Mines Limited (NYSE: AEM) (TSX: AEM) and Yamana Gold Inc. (TSX: YRI; NYSE: AUY; LSE: AUY).

“We created SESG to fill a gap in the marketplace with a gold fund focused on trust, transparency, and traceability. Our goal is to answer a number of key questions for investors: where does my gold come from, who produced it and was it produced sustainably by recognized ESG leaders? Through our partnership with the Royal Canadian Mint and our relationships with leading Canadian gold producers, Sprott is uniquely positioned to offer a convenient way for investors to own physical gold that aligns with their ESG values,” said John Ciampaglia, CEO of Sprott Asset Management.

“At Agnico Eagle, we believe in operating responsibly and contributing positively to the communities in which we operate. We understand that ESG considerations are an opportunity to drive improved performance and deliver on our vision to build a high-value business. We believe that we are recognized within the mining industry for our global leading ESG practices, for having one of the lowest GHG intensities and for operating in safe jurisdictions. Agnico Eagle is proud to be a partner of choice as a trusted source of responsibly produced gold for this first ESG Gold Fund,” said Carol Plummer, Agnico Eagle’s Executive Vice President, Operational Excellence.

“The gold industry must do everything possible to ensure its gold is produced in the most sustainable and responsible way. This has been a fundamental value of Yamana’s since we first started operating, a fact reflected by our strong track record in ESG which has been consistently recognized by independent ratings agencies and other stakeholders, including the recent publication of Canada’s Best 50 Corporate Citizens by Corporate Knights, in which Yamana was named as the highest-ranked mining company. It is vital that we protect our operating environments and maximize the positive impact we have in host communities. That is why we are delighted to partner with Sprott in the first-ever ESG-focused physical gold fund established specifically to acquire gold that is underpinned by strong ESG fundamentals. We believe that Yamana’s inclusion in this fund reflects our strong performance and commitment to push boundaries in the industry to deliver responsibly mined gold ounces that benefit all,” said Daniel Racine, President, and CEO of Yamana Gold.

“The Mint is pleased to support this innovative new product. It is an initiative that reinforces the Mint’s strong commitment to ESG practices,” said Tom Froggatt, Chief Commercial Officer of the Royal Canadian Mint.

SESG Investment Objective

SESG’s investment objective is to closely reflect the performance of the price of gold by holding physical gold bullion that meets certain environmental, social and governance standards and criteria determined by the Sponsor and defined as “Sprott ESG Approved Gold”. The Fund is expected to consist primarily of fully allocated unencumbered physical gold bullion held by the Mint on behalf of the Fund that qualifies as Sprott ESG Approved Gold, plus from time to time gold in unallocated form.

Methodology

Sprott will identify world-class North American gold mining companies with proven, highly transparent ESG track records. Selected gold miners will also undergo additional due diligence conducted at individual mine sites to ensure they are meeting local ESG best practices. These gold mining companies and mine sites must also maintain compliance with the RCM’s Responsible Sourcing Requirements for refining customers, including the RCM’s Responsible Metals Program. To ensure the provenance and integrity of ESG Approved Gold, the RCM will segregate its supply chain and refining activities.

Sprott has filed a registration statement relating to this Offering, including a prospectus, with the SEC and it is available at the SEC’s website at http://www.sec.gov. Before you invest, you should read the prospectus in that registration statement and any other documents Sprott has filed with the SEC for more complete information about SESG and this Offering. You may get these documents for free by visiting EDGAR or the SEC website at

www.sec.gov

. Alternatively, you can obtain a copy of the prospectus related to the Offering by calling toll-free at
855.943.8099
or by email at [email protected].

About Sprott

Sprott Asset Management LP is a wholly-owned subsidiary of Sprott Inc. (“Sprott”). Sprott is a global leader in precious metal and real assets investments. We are specialists. Our in-depth knowledge, experience, and, relationships separate us from the generalists. Our investment strategies include Exchange Listed Products, Managed Equities, Private Strategies, and Brokerage. Sprott has offices in Toronto, New York, and London, and the company’s common shares are listed on the New York Stock Exchange and the Toronto Stock Exchange under the symbol (SII). For more information, please visit www.sprott.com.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (collectively, “forward-looking statements”) within the meaning of applicable securities laws. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. In particular, but without limiting the forgoing, this press release contains forward-looking statements pertaining to the launch and trading of the Fund.

Forward-looking statements contained herein are made as of the date of this press release and Sprott disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Sprott undertakes no obligation to update forward-looking statements if circumstances, management’s estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements contained in this press release concerning the launch of the Fund or the timing of the trading of its shares on NYSE Arca.

Investor contact:

Glen Williams
Managing Director
Investor and Institutional Client Relations
Head of Corporate Communications
(416) 943-4394
[email protected]

Media contact:

Dan Gagnier / Jeffrey Mathews
Gagnier Communications
(646) 569-5897
[email protected]



Zebra Technologies Announces Second-Quarter 2022 Results

Zebra Technologies Announces Second-Quarter 2022 Results

Second-Quarter Financial Highlights

  • Net sales of $1,468 million; year-over-year increase of 6.6%
  • Net loss of $98 million and net loss per diluted share of $(1.87), inclusive of $372 million in settlement costs
  • Non-GAAP diluted EPS increased 0.9% year-over-year to $4.61
  • Adjusted EBITDA decreased 1.2% year-over-year to $321 million

LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–Zebra Technologies Corporation (NASDAQ: ZBRA), an innovator at the edge of the enterprise with solutions and partners that enable businesses to gain a performance edge, today announced results for the second quarter ended July 2, 2022.

“Our team delivered solid second quarter results, executing well in a challenging macro environment. Sales growth was near the high end of our expectations, and we were able to deliver adjusted earnings per share growth over the prior year, despite continued elevated supply chain costs and foreign currency exchange headwinds,” said Anders Gustafsson, Chief Executive Officer of Zebra Technologies.

“We have a strong order backlog and robust pipeline of business that supports solid growth in the second half of 2022. For the full year, we are maintaining our sales outlook and adjusting EBITDA margin to the low end of our previous outlook to reflect the impact of the stronger U.S. Dollar and the recent Matrox Imaging acquisition. Although supply chain costs remain elevated, we continue to drive improvement through the actions we are taking. We are excited about the early traction we are seeing in our expansion markets which elevate Zebra’s customer value proposition.”

$ in millions, except per share amounts

2Q22

2Q21

Change

Select reported measures:

 

 

 

Net sales

$

1,468

 

$

1,377

 

6.6%

Gross profit

 

674

 

 

658

 

2.4%

Gross margin

 

45.9

%

 

47.8

%

(190) bps

Net (loss) income

 

(98

)

 

219

 

(144.7%)

Net (loss) income margin

 

(6.7

)%

 

15.9

%

NM (1)

Net (loss) income per diluted share

$

(1.87

)

$

4.07

 

(145.9%)

 

 

 

 

Select Non-GAAP measures:

 

 

 

Adjusted net sales

$

1,468

 

$

1,380

 

6.4%

Organic net sales growth

 

 

6.9%

Adjusted gross profit

 

675

 

 

663

 

1.8%

Adjusted gross margin

 

46.0

%

 

48.0

%

(200) bps

Adjusted EBITDA

 

321

 

 

325

 

(1.2%)

Adjusted EBITDA margin

 

21.9

%

 

23.6

%

(170) bps

Non-GAAP net income

$

243

 

$

247

 

(1.6%)

Non-GAAP earnings per diluted share

$

4.61

 

$

4.57

 

0.9%

(1) Not meaningful

Net sales were $1,468 million in the second quarter of 2022 compared to $1,377 million in the second quarter of 2021. Net sales in the Enterprise Visibility & Mobility (“EVM”) segment were $1,022 million in the second quarter of 2022 compared with $966 million in the second quarter of 2021. Asset Intelligence & Tracking (“AIT”) segment net sales were $446 million in the second quarter of 2022 compared to $414 million in the prior year period. Consolidated organic net sales for the second quarter increased 6.9%. Second-quarter year-over-year organic net sales increased by 5.6% in the EVM segment and increased by 9.7% in the AIT segment.

Second quarter 2022 gross profit was $674 million compared to $658 million in the prior year period. Gross margin decreased to 45.9% for the second quarter of 2022 compared to 47.8% in the prior year period. The decrease was primarily due to higher premium supply chain costs and China import tariff recoveries in the prior year period. Adjusted gross margin was 46.0% in the second quarter of 2022 compared to 48.0% in the prior year period.

Operating expenses increased in the second quarter of 2022 to $819 million from $411 million in the prior year period, primarily due to a $372 million charge for settlement and related costs, and expenses associated with recently acquired businesses. Adjusted operating expenses increased in the second quarter of 2022 to $370 million from $356 million in the prior year period.

Net loss for the second quarter of 2022 was $98 million, or $1.87 loss per diluted share, compared to net income of $219 million, or $4.07 per diluted share, for the second quarter of 2021. Non-GAAP net income for the second quarter of 2022 decreased to $243 million, or $4.61 per diluted share, compared to $247 million, or $4.57 per diluted share, for the prior year period.

Adjusted EBITDA for the second quarter of 2022 decreased to $321 million, or 21.9% of adjusted net sales, compared to $325 million, or 23.6% of adjusted net sales for the second quarter of 2021 due to lower gross margin partially offset by adjusted operating expense leverage.

Balance Sheet and Cash Flow

As of July 2, 2022, the company had cash and cash equivalents of $98 million and total debt of $2,171 million.

For the first six months of 2022, the company generated $154 million of operating cash flow and made capital expenditures of $31 million, resulting in free cash flow of $123 million. The Company also acquired Matrox for $875 million, made $605 million of share repurchases under its existing authorization, and had net debt proceeds of $1,175 million.

As previously announced in the second quarter, the company refinanced its debt and expanded its liquidity with a $3.25 billion senior secured credit facility maturing May 2027. This facility includes a $1.75 billion term loan, and a $1.5 billion revolving credit facility. The company has retired its $875 million term loan and $1.0 billion revolving credit facility.

Outlook

Third Quarter 2022

The company expects third quarter 2022 adjusted net sales to increase 2% to 4% compared to the third quarter of 2021. This expectation includes an approximately 2 point additive impact from recently acquired businesses, and an approximately 3 point negative impact from foreign currency translation.

Adjusted EBITDA margin for the third quarter of 2022 is expected to be approximately 22%, which includes approximately $45 million of premium supply chain costs. Non-GAAP earnings per diluted share are expected to be in the range of $4.35 to $4.65. This assumes an adjusted effective tax rate of approximately 18%.

Full Year 2022

The Company is narrowing the range of its full year outlook for adjusted net sales growth to 4% to 6% from 2021. This expectation includes an approximately 150 basis point additive impact from recently acquired businesses, and an approximately 225 basis point negative impact from foreign currency translation. Adjusted EBITDA margin for the full year is expected to be approximately 22%, the low end of its previous outlook due to foreign currency headwinds. This outlook assumes approximately $200 million impact from premium supply chain costs.

Free cash flow is now expected to be at least $650 million, inclusive of the anticipated $150 million of settlement and related payments.

The company does not provide a reconciliation for non-GAAP estimates on a forward-looking basis where it is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing or amount of the most directly comparable forward-looking GAAP financial measure as discussed under the “Forward-Looking Statements” caption below. This would include items that have not yet occurred, are out of the company’s control and/or cannot be reasonably predicted, and that would impact diluted net earnings per share. For the same reasons, the company is unable to address the probable significance of the unavailable information. Forward-looking non-GAAP financial measures provided without the most directly comparable GAAP financial measures may vary materially from the corresponding GAAP financial measures.

Conference Call Notification

Investors are invited to listen to a live webcast of Zebra’s conference call regarding the company’s financial results. The conference call will be held today, Tuesday Aug 2, at 7:30 a.m. Central Time (8:30 a.m. Eastern Time). To view the webcast, visit the investor relations section of the company’s website at investors.zebra.com.

About Zebra

Zebra (NASDAQ: ZBRA) empowers organizations to thrive in the on-demand economy by making every front-line worker and asset at the edge visible, connected and fully optimized. With an ecosystem of more than 10,000 partners across more than 100 countries, Zebra serves customers of all sizes – including 94% of the Fortune 100 – with an award-winning portfolio of hardware, software, services and solutions that digitize and automate workflows. Supply chains are more dynamic, customers and patients are better served, and workers are more engaged when they utilize Zebra innovations that help them sense, analyze and act in real time. Zebra recently expanded its industrial automation portfolio with its Fetch Robotics acquisition and increased its machine vision and AI software capabilities with the acquisitions of Adaptive Vision, antuit.ai and Matrox Imaging. Zebra is #25 on Newsweek’s inaugural list of America’s 100 Most Loved Workplaces and #79 on Forbes’ list of America’s 500 Best Midsize Employers. Learn more at www.zebra.com or sign up for news alerts. Follow Zebra’s Your Edge blog, LinkedIn, Twitter and Facebook, and check out our Story Hub: Zebra Perspectives.

Forward-Looking Statements

This press release contains forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements regarding the company’s outlook. Actual results may differ from those expressed or implied in the company’s forward-looking statements. These statements represent estimates only as of the date they were made. Zebra undertakes no obligation, other than as may be required by law, to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason after the date of this release.

These forward-looking statements are based on current expectations, forecasts and assumptions and are subject to the risks and uncertainties inherent in Zebra’s industry, market conditions, general domestic and international economic conditions, and other factors. These factors include customer acceptance of Zebra’s offerings and competitors’ offerings and the potential effects of emerging technologies and changes in customer requirements. The effect of global market conditions, and the availability of credit and capital markets volatility may have adverse effects on Zebra, its suppliers and its customers. In addition, natural disasters, man-made disasters, public health issues (including pandemics), and cybersecurity incidents may have negative effects on our business and results of operations. Our ability to purchase sufficient materials, parts, and components as well as our ability to provide services and software to meet customer demand could negatively impact our results of operations and customer relationships. Profits and profitability may be affected by Zebra’s ability to control manufacturing and operating costs. Because of its debt, interest rates and financial market conditions may also have an impact on results. Foreign exchange rates, customs duties and trade policies may have an effect on financial results because of the large percentage of our international sales. The impacts of changes in foreign and domestic governmental policies, regulations, or laws, as well as the outcome of litigation or tax matters in which Zebra may be involved are other factors. The success of integrating acquisitions could also affect profitability, reported results and the company’s competitive position in its industry. These and other factors could have an adverse effect on Zebra’s sales, gross profit margins and results of operations and increase the volatility of our financial results. When used in this release and documents referenced, the words “anticipate,” “believe,” “outlook,” and “expect” and similar expressions, as they relate to the company or its management, are intended to identify such forward-looking statements, but are not the exclusive means of identifying these statements. Descriptions of the risks, uncertainties and other factors that could affect the company’s future operations and results can be found in Zebra’s filings with the Securities and Exchange Commission, including the company’s most recent Form 10-K and Form 10-Q.

Use of Non-GAAP Financial Information

This press release contains certain Non-GAAP financial measures, consisting of “adjusted net sales,” “adjusted gross profit,” “EBITDA,” “Adjusted EBITDA,” “Non-GAAP net income,” “Non-GAAP earnings per share,” “free cash flow,” “organic net sales growth,” and “adjusted operating expenses.” Management presents these measures to focus on the on-going operations and believes it is useful to investors because they enable them to perform meaningful comparisons of past and present operating results. The company believes it is useful to present non-GAAP financial measures, which exclude certain significant items, as a means to understand the performance of its ongoing operations and how management views the business. Please see the “Reconciliation of GAAP to Non-GAAP Financial Measures” tables and accompanying disclosures at the end of this press release for more detailed information regarding non-GAAP financial measures herein, including the items reflected in adjusted net earnings calculations. These measures, however, should not be construed as an alternative to any other measure of performance determined in accordance with GAAP.

The company does not provide a reconciliation for non-GAAP estimates on a forward-looking basis (including the information under “Outlook” above) where it is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing or amount of various items that have not yet occurred, are out of the company’s control and/or cannot be reasonably predicted, and that would impact diluted net earnings per share, the most directly comparable forward-looking GAAP financial measure. For the same reasons, the company is unable to address the probable significance of the unavailable information. Forward-looking non-GAAP financial measures provided without the most directly comparable GAAP financial measures may vary materially from the corresponding GAAP financial measures.

As a global company, Zebra’s operating results reported in U.S. dollars are affected by foreign currency exchange rate fluctuations because the underlying foreign currencies in which the company transacts change in value over time compared to the U.S. dollar; accordingly, the company presents certain organic growth financial information, which includes impacts of foreign currency translation, to provide a framework to assess how the company’s businesses performed excluding the impact of foreign currency exchange rate fluctuations. Foreign currency impact represents the difference in results that are attributable to fluctuations in the currency exchange rates used to convert the results for businesses where the functional currency is not the U.S. dollar. This impact is calculated by translating current period results at the currency exchange rates used in the comparable period in the prior year, rather than the exchange rates in effect during the current period. In addition, the company excludes the impact of its foreign currency hedging program in the prior year periods. The company believes these measures should be considered a supplement to and not in lieu of the company’s performance measures calculated in accordance with GAAP.

ZEBRA TECHNOLOGIES CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In millions, except share data)

 

 

July 2,

2022

 

December 31,

2021

 

(Unaudited)

 

 

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

98

 

 

$

332

 

Accounts receivable, net of allowances for doubtful accounts of $1 million each as of July 2, 2022 and December 31, 2021

 

925

 

 

 

752

 

Inventories, net

 

632

 

 

 

491

 

Income tax receivable

 

20

 

 

 

8

 

Prepaid expenses and other current assets

 

131

 

 

 

106

 

Total Current assets

 

1,806

 

 

 

1,689

 

Property, plant and equipment, net

 

265

 

 

 

272

 

Right-of-use lease assets

 

174

 

 

 

131

 

Goodwill

 

3,929

 

 

 

3,265

 

Other intangibles, net

 

659

 

 

 

469

 

Deferred income taxes

 

311

 

 

 

192

 

Other long-term assets

 

241

 

 

 

197

 

Total Assets

$

7,385

 

 

$

6,215

 

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities:

 

 

 

Current portion of long-term debt

$

144

 

 

$

69

 

Accounts payable

 

827

 

 

 

700

 

Accrued liabilities

 

714

 

 

 

639

 

Deferred revenue

 

413

 

 

 

380

 

Income taxes payable

 

15

 

 

 

12

 

Total Current liabilities

 

2,113

 

 

 

1,800

 

Long-term debt

 

2,017

 

 

 

922

 

Long-term lease liabilities

 

155

 

 

 

121

 

Deferred income taxes

 

71

 

 

 

6

 

Long-term deferred revenue

 

318

 

 

 

315

 

Other long-term liabilities

 

198

 

 

 

67

 

Total Liabilities

 

4,872

 

 

 

3,231

 

Stockholders’ Equity:

 

 

 

Preferred stock, $.01 par value; authorized 10,000,000 shares; none issued

 

 

 

 

 

Class A common stock, $.01 par value; authorized 150,000,000 shares; issued 72,151,857 shares

 

1

 

 

 

1

 

Additional paid-in capital

 

512

 

 

 

462

 

Treasury stock at cost, 20,196,863 and 18,736,582 shares as of July 2, 2022 and December 31, 2021, respectively

 

(1,652

)

 

 

(1,023

)

Retained earnings

 

3,680

 

 

 

3,573

 

Accumulated other comprehensive loss

 

(28

)

 

 

(29

)

Total Stockholders’ Equity

 

2,513

 

 

 

2,984

 

Total Liabilities and Stockholders’ Equity

$

7,385

 

 

$

6,215

 

ZEBRA TECHNOLOGIES CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(In millions, except share data)

(Unaudited)

 

 

Three Months Ended

 

Six Months Ended

 

July 2,

2022

 

July 3,

2021

 

July 2,

2022

 

July 3,

2021

Net sales:

 

 

 

 

 

 

 

Tangible products

$

1,259

 

 

$

1,192

 

 

$

2,466

 

 

$

2,345

 

Services and software

 

209

 

 

 

185

 

 

 

434

 

 

 

379

 

Total Net sales

 

1,468

 

 

 

1,377

 

 

 

2,900

 

 

 

2,724

 

Cost of sales:

 

 

 

 

 

 

 

Tangible products

 

685

 

 

 

618

 

 

 

1,366

 

 

 

1,209

 

Services and software

 

109

 

 

 

101

 

 

 

223

 

 

 

202

 

Total Cost of sales

 

794

 

 

 

719

 

 

 

1,589

 

 

 

1,411

 

Gross profit

 

674

 

 

 

658

 

 

 

1,311

 

 

 

1,313

 

Operating expenses:

 

 

 

 

 

 

 

Selling and marketing

 

151

 

 

 

148

 

 

 

303

 

 

 

282

 

Research and development

 

148

 

 

 

141

 

 

 

285

 

 

 

281

 

General and administrative

 

97

 

 

 

92

 

 

 

196

 

 

 

174

 

Settlement and related costs

 

372

 

 

 

 

 

 

372

 

 

 

 

Amortization of intangible assets

 

35

 

 

 

26

 

 

 

68

 

 

 

52

 

Acquisition and integration costs

 

14

 

 

 

4

 

 

 

18

 

 

 

5

 

Exit and restructuring costs

 

2

 

 

 

 

 

 

2

 

 

 

 

Total Operating expenses

 

819

 

 

 

411

 

 

 

1,244

 

 

 

794

 

Operating (loss) income

 

(145

)

 

 

247

 

 

 

67

 

 

 

519

 

Other (loss) income, net:

 

 

 

 

 

 

 

Foreign exchange (loss) gain

 

(3

)

 

 

(1

)

 

 

5

 

 

 

1

 

Interest (expense) income, net

 

(3

)

 

 

(7

)

 

 

27

 

 

 

(5

)

Other (expense) income, net

 

(2

)

 

 

(1

)

 

 

(2

)

 

 

(1

)

Total Other (expense) income, net

 

(8

)

 

 

(9

)

 

 

30

 

 

 

(5

)

(Loss) income before income tax

 

(153

)

 

 

238

 

 

 

97

 

 

 

514

 

Income tax (benefit) expense

 

(55

)

 

 

19

 

 

 

(10

)

 

 

67

 

Net (loss) income

$

(98

)

 

$

219

 

 

$

107

 

 

$

447

 

Basic (loss) earnings per share

$

(1.87

)

 

$

4.10

 

 

$

2.04

 

 

$

8.36

 

Diluted (loss) earnings per share

$

(1.87

)

 

$

4.07

 

 

$

2.02

 

 

$

8.29

 

ZEBRA TECHNOLOGIES CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)

(Unaudited)

 

 

Six Months Ended

 

July 2,

2022

 

July 3,

2021

Cash flows from operating activities:

 

 

 

Net income

$

107

 

 

$

447

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

Depreciation and amortization

 

103

 

 

 

88

 

Share-based compensation

 

42

 

 

 

38

 

Deferred income taxes

 

(124

)

 

 

(5

)

Unrealized gain on forward interest rate swaps

 

(52

)

 

 

(13

)

Other, net

 

3

 

 

 

1

 

Changes in operating assets and liabilities:

 

 

 

Accounts receivable, net

 

(170

)

 

 

(59

)

Inventories, net

 

(108

)

 

 

26

 

Other assets

 

(52

)

 

 

(22

)

Accounts payable

 

121

 

 

 

(10

)

Accrued liabilities

 

(77

)

 

 

2

 

Deferred revenue

 

34

 

 

 

67

 

Income taxes

 

(9

)

 

 

(23

)

Settlement and related costs, net

 

320

 

 

 

 

Other operating activities

 

16

 

 

 

2

 

Net cash provided by operating activities

 

154

 

 

 

539

 

Cash flows from investing activities:

 

 

 

Acquisition of businesses, net of cash acquired

 

(875

)

 

 

(17

)

Purchases of property, plant and equipment

 

(31

)

 

 

(25

)

Purchases of long-term investments

 

(6

)

 

 

(17

)

Net cash used in investing activities

 

(912

)

 

 

(59

)

Cash flows from financing activities:

 

 

 

Payment of debt issuance costs, extinguishment costs and discounts

 

(8

)

 

 

 

Payments of long-term debt

 

(119

)

 

 

(264

)

Proceeds from issuance of long-term debt

 

1,294

 

 

 

8

 

Payments for repurchases of common stock

 

(605

)

 

 

(25

)

Net payments related to share-based compensation plans

 

(16

)

 

 

(46

)

Change in unremitted cash collections from servicing factored receivables

 

(28

)

 

 

(2

)

Net cash provided by (used in) financing activities

 

518

 

 

 

(329

)

Effect of exchange rate changes on cash and cash equivalents, including restricted cash

 

(6

)

 

 

(4

)

Net (decrease) increase in cash and cash equivalents, including restricted cash

 

(246

)

 

 

147

 

Cash and cash equivalents, including restricted cash, at beginning of period

 

344

 

 

 

192

 

Cash and cash equivalents, including restricted cash, at end of period

$

98

 

 

$

339

 

Less restricted cash, included in Prepaid expenses and other current assets

 

 

 

 

(21

)

Cash and cash equivalents at end of period

$

98

 

 

$

318

 

Supplemental disclosures of cash flow information:

 

 

 

Income taxes paid

$

120

 

 

$

94

 

Interest paid

$

15

 

 

$

17

 

ZEBRA TECHNOLOGIES CORPORATION AND SUBSIDIARIES

RECONCILIATION OF ORGANIC NET SALES GROWTH

(Unaudited)

 

 

Three Months Ended

 

July 2, 2022

 

AIT

 

EVM

 

Consolidated

Reported GAAP Consolidated Net sales growth

7.7

%

 

5.8

%

 

6.6

%

Adjustments:

 

 

 

 

 

Impact of foreign currency translation (1)

2.0

%

 

1.8

%

 

2.0

%

Impact of acquisitions (2)

%

 

(2.0

)%

 

(1.7

)%

Consolidated Organic Net sales growth

9.7

%

 

5.6

%

 

6.9

%

 

 

 

 

 

 

 

Six Months Ended

 

July 2, 2022

 

AIT

 

EVM

 

Consolidated

Reported GAAP Consolidated Net sales growth

(0.4

) %

 

9.2

%

 

6.5

%

Adjustments:

 

 

 

 

 

Impact of foreign currency translation (1)

1.1

%

 

1.0

%

 

0.8

%

Impact of acquisitions (2)

%

 

(1.6

)%

 

(1.2

)%

Consolidated Organic Net sales growth

0.7

%

 

8.6

%

 

6.1

%

(1)

Operating results reported in U.S. Dollars are affected by foreign currency exchange rate fluctuations. Foreign currency translation impact represents the difference in results that are attributable to fluctuations in the currency exchange rates used to convert the results for businesses where the functional currency is not the U.S. Dollar. This impact is calculated by translating the current period results at the currency exchange rates used in the comparable prior year period, inclusive of the Company’s foreign currency hedging program.

(2)

For purposes of computing Organic Net sales growth, amounts directly attributable to the acquisitions of Adaptive Vision, Fetch, Antuit and Matrox are excluded for twelve months following their respective acquisitions.

ZEBRA TECHNOLOGIES CORPORATION AND SUBSIDIARIES

RECONCILIATION OF GAAP TO NON-GAAP GROSS MARGIN

(In millions)

(Unaudited)

 

 

Three Months Ended

 

July 2, 2022

 

July 3, 2021

 

AIT

 

EVM

 

Consolidated

 

AIT

 

EVM

 

Consolidated

GAAP

 

 

 

 

 

 

 

 

 

 

 

Reported Net sales (1)

$

446

 

 

$

1,022

 

 

$

1,468

 

 

$

414

 

 

$

966

 

 

$

1,377

 

Reported Gross profit (1)

 

195

 

 

 

479

 

 

 

674

 

 

 

199

 

 

 

462

 

 

 

658

 

Gross Margin

 

43.7

%

 

 

46.9

%

 

 

45.9

%

 

 

48.1

%

 

 

47.8

%

 

 

47.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP

 

 

 

 

 

 

 

 

 

 

 

Adjusted Net sales

$

446

 

 

$

1,022

 

 

$

1,468

 

 

$

414

 

 

$

966

 

 

$

1,380

 

Adjusted Gross profit (2)

 

195

 

 

 

480

 

 

 

675

 

 

 

200

 

 

 

463

 

 

 

663

 

Adjusted Gross Margin

 

43.7

%

 

 

47.0

%

 

 

46.0

%

 

 

48.3

%

 

 

47.9

%

 

 

48.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Six Months Ended

 

July 2, 2022

 

July 3, 2021

 

AIT

 

EVM

 

Consolidated

 

AIT

 

EVM

 

Consolidated

GAAP

 

 

 

 

 

 

 

 

 

 

 

Reported Net sales (1)

$

840

 

 

$

2,060

 

 

$

2,900

 

 

$

843

 

 

$

1,887

 

 

$

2,724

 

Reported Gross profit (1)

 

349

 

 

 

962

 

 

 

1,311

 

 

 

406

 

 

 

913

 

 

 

1,313

 

Gross Margin

 

41.5

%

 

 

46.7

%

 

 

45.2

%

 

 

48.2

%

 

 

48.4

%

 

 

48.2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP

 

 

 

 

 

 

 

 

 

 

 

Adjusted Net sales

$

840

 

 

$

2,060

 

 

$

2,900

 

 

$

843

 

 

$

1,887

 

 

$

2,730

 

Adjusted Gross profit (2)

 

349

 

 

 

964

 

 

 

1,313

 

 

 

407

 

 

 

916

 

 

 

1,323

 

Adjusted Gross Margin

 

41.5

%

 

 

46.8

%

 

 

45.3

%

 

 

48.3

%

 

 

48.5

%

 

 

48.5

%

(1)

Consolidated results include corporate eliminations related to business acquisition purchase accounting adjustments that are not reported in segment results.

(2)

Adjusted Gross profit excludes business acquisition purchase accounting adjustments and share-based compensation expense.

ZEBRA TECHNOLOGIES CORPORATION AND SUBSIDIARIES

RECONCILIATION OF GAAP TO NON-GAAP NET INCOME

(In millions, except share data)

(Unaudited)

 

 

Three Months Ended

 

Six Months Ended

 

July 2,

2022

 

July 3,

2021

 

July 2,

2022

 

July 3,

2021

Net income

$

(98

)

 

$

219

 

 

$

107

 

 

$

447

 

Adjustments to Net sales(1)

 

 

 

 

 

 

 

Purchase accounting adjustments

 

 

 

 

3

 

 

 

 

 

 

6

 

Total adjustments to Net sales

 

 

 

 

3

 

 

 

 

 

 

6

 

Adjustments to Cost of sales(1)

 

 

 

 

 

 

 

Share-based compensation

 

1

 

 

 

2

 

 

 

2

 

 

 

4

 

Total adjustments to Cost of sales

 

1

 

 

 

2

 

 

 

2

 

 

 

4

 

Adjustments to Operating expenses(1)

 

 

 

 

 

 

 

Amortization of intangible assets

 

35

 

 

 

26

 

 

 

68

 

 

 

52

 

Acquisition and integration costs

 

14

 

 

 

4

 

 

 

18

 

 

 

5

 

Settlement and related costs

 

372

 

 

 

 

 

 

372

 

 

 

 

Share-based compensation

 

26

 

 

 

25

 

 

 

42

 

 

 

44

 

Exit and restructuring costs

 

2

 

 

 

 

 

 

2

 

 

 

 

Total adjustments to Operating expenses

 

449

 

 

 

55

 

 

 

502

 

 

 

101

 

Adjustments to Other income (expense), net(1)

 

 

 

 

 

 

 

Amortization of debt issuance costs and discounts

 

4

 

 

 

1

 

 

 

4

 

 

 

2

 

Investment gain

 

 

 

 

1

 

 

 

 

 

 

 

Foreign exchange loss / (gain)

 

3

 

 

 

1

 

 

 

(5

)

 

 

(1

)

Forward interest rate swap (gain) / loss

 

(11

)

 

 

3

 

 

 

(45

)

 

 

(5

)

Total adjustments to Other income (expense), net

 

(4

)

 

 

6

 

 

 

(46

)

 

 

(4

)

Income tax effect of adjustments(2)

 

 

 

 

 

 

 

Reported income tax expense

 

(55

)

 

 

19

 

 

 

(10

)

 

 

67

 

Less: Adjusted income tax expense

 

(50

)

 

 

(57

)

 

 

(98

)

 

 

(116

)

Total adjustments to income tax

 

(105

)

 

 

(38

)

 

 

(108

)

 

 

(49

)

Total adjustments

 

341

 

 

 

28

 

 

 

350

 

 

 

58

 

Non-GAAP Net income

$

243

 

 

$

247

 

 

$

457

 

 

$

505

 

 

 

 

 

 

 

 

 

GAAP earnings per share

 

 

 

 

 

 

 

Basic

$

(1.87

)

 

$

4.10

 

 

$

2.04

 

 

$

8.36

 

Diluted

$

(1.87

)

 

$

4.07

 

 

$

2.02

 

 

$

8.29

 

Non-GAAP earnings per share

 

 

 

 

 

 

 

Basic

$

4.64

 

 

$

4.61

 

 

$

8.68

 

 

$

9.44

 

Diluted

$

4.61

 

 

$

4.57

 

 

$

8.61

 

 

$

9.36

 

 

 

 

 

 

 

 

 

Basic weighted average shares outstanding (3)

 

52,138,470

 

 

 

53,449,143

 

 

 

52,642,348

 

 

 

53,460,495

 

Diluted weighted average and equivalent shares outstanding (3)

 

52,138,470

 

 

 

53,908,295

 

 

 

53,033,729

 

 

 

53,930,103

 

(1)

Presented on a pre-tax basis.

(2)

Represents adjustments to GAAP income tax expense commensurate with pre-tax non-GAAP adjustments (including the resulting impacts to U.S. BEAT/GILTI provisions), as well as adjustments to exclude the impacts of certain discrete income tax items and incorporate the anticipated annualized effects of current year tax planning.

(3)

For GAAP purposes, in periods of a net loss, restricted stock and performance share awards, which are participating securities, are excluded from weighted-average shares outstanding and all unvested share-based awards were anti-dilutive and therefore excluded from diluted shares. For the three months ended July 2, 2022, Non-GAAP basic and diluted weighted average shares outstanding were 52,298,897 and 52,656,342, respectively.

ZEBRA TECHNOLOGIES CORPORATION AND SUBSIDIARIES

GAAP to NON-GAAP RECONCILIATION TO EBITDA

(In millions)

(Unaudited)

 

 

Three Months Ended

 

Six Months Ended

 

July 2,

2022

 

July 3,

2021

 

July 2,

2022

 

July 3,

2021

Net income

$

(98

)

 

$

219

 

 

$

107

 

 

$

447

 

Add back:

 

 

 

 

 

 

 

Depreciation

 

16

 

 

 

18

 

 

 

35

 

 

 

36

 

Amortization of intangible assets

 

35

 

 

 

26

 

 

 

68

 

 

 

52

 

Total Other (expense) income, net

 

8

 

 

 

9

 

 

 

(30

)

 

 

5

 

Income tax (benefit) expense

 

(55

)

 

 

19

 

 

 

(10

)

 

 

67

 

EBITDA (Non-GAAP)

 

(94

)

 

 

291

 

 

 

170

 

 

 

607

 

 

 

 

 

 

 

 

 

Adjustments to Net sales

 

 

 

 

 

 

 

Purchase accounting adjustments

 

 

 

 

3

 

 

 

 

 

 

6

 

Total adjustments to Net sales

 

 

 

 

3

 

 

 

 

 

 

6

 

Adjustments to Cost of sales

 

 

 

 

 

 

 

Share-based compensation

 

1

 

 

 

2

 

 

 

2

 

 

 

4

 

Total adjustments to Cost of sales

 

1

 

 

 

2

 

 

 

2

 

 

 

4

 

Adjustments to Operating expenses

 

 

 

 

 

 

 

Acquisition and integration costs

 

14

 

 

 

4

 

 

 

18

 

 

 

5

 

Settlement and related costs

 

372

 

 

 

 

 

 

372

 

 

 

 

Share-based compensation

 

26

 

 

 

25

 

 

 

42

 

 

 

44

 

Exit and restructuring costs

 

2

 

 

 

 

 

 

2

 

 

 

 

Total adjustments to Operating expenses

 

414

 

 

 

29

 

 

 

434

 

 

 

49

 

Total adjustments to EBITDA

 

415

 

 

 

34

 

 

 

436

 

 

 

59

 

Adjusted EBITDA (Non-GAAP)

$

321

 

 

$

325

 

 

$

606

 

 

$

666

 

 

 

 

 

 

 

 

 

Adjusted EBITDA % of Adjusted Net Sales

 

21.9

%

 

 

23.6

%

 

 

20.9

%

 

 

24.4

%

FREE CASH FLOW

 

 

Six Months Ended

 

July 2,

2022

 

July 3,

2021

Net cash provided by operating activities

$

154

 

 

$

539

 

Less: Purchases of property, plant and equipment

 

(31

)

 

 

(25

)

Free cash flow (Non-GAAP)(1)

$

123

 

 

$

514

 

(1)

Free cash flow is defined as Net cash provided by operating activities in a period minus purchases of property, plant and equipment (capital expenditures) made in that period. This measure does not represent residual cash flows available for discretionary expenditures as the measure does not deduct the payments required for debt service and other contractual obligations or payments for future business acquisitions. Therefore, we believe it is important to view free cash flow as a measure that provides supplemental information to our entire statements of cash flows.

 

Investors

Michael Steele, CFA, IRC

Vice President, Investor Relations

Phone: + 1 847 793 6707

[email protected]

Media

Therese Van Ryne

Senior Director, External Communications

Phone: + 1 847 370 2317

[email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Software Hardware Electronic Design Automation Artificial Intelligence Robotics Technology Supply Chain Management Retail

MEDIA:

Logo
Logo

BrightView Prepares for Major League Baseball’s Field of Dreams Sequel

BrightView Prepares for Major League Baseball’s Field of Dreams Sequel

Official Field Consultant of MLB brings ballpark to life in an Iowa cornfield

BLUE BELL, Pa.–(BUSINESS WIRE)–
We built it and they’re coming… again! As anticipation builds for the encore to last year’s MLB at Field of Dreams game, BrightView (NYSE: BV), the Official Field Consultant of Major League Baseball, is deep in the thick of a Dyersville, Iowa cornfield fine tuning and carefully manicuring the major league field inspired by the beloved 1989 film.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220802005133/en/

BrightView, the Official Field Consultant of Major League Baseball, is working with MLB to prepare the ballfield for the 2022 edition of the Field of Dreams game. (Photo: Business Wire)

BrightView, the Official Field Consultant of Major League Baseball, is working with MLB to prepare the ballfield for the 2022 edition of the Field of Dreams game. (Photo: Business Wire)

With the second installment of the Field of Dreams classic scheduled for August 11, BrightView is again working with MLB to bring this vision to life and ensure the field conforms to major league playing standards. And the sequel, featuring the Cincinnati Reds and Chicago Cubs, promises to be just as epic.

Since MLB announced the Field of Dreams series in 2019, BrightView has worked with MLB to draw up plans and carve out and maintain an MLB caliber ballfield in a cornfield adjacent to the Dyersville farm where the movie was filmed and the original field still stands. In fact, the distance from the movie site’s homeplate to the MLB field’s homeplate is exactly 1,000 feet.

Led by Murray Cook, President of BrightView’s Sports Turf division, BrightView performed all site work and constructed the ballfield, bullpens, fencing, and foul poles, as well as oversaw installation of the outfield wall, backstop net, and various player-related areas. The team also managed the planting of the corn that is part of the iconic outfield background.

“This was an incredibly satisfying project,” said Cook. “Our goal was to build a field that not only replicates the Field of Dreams movie magic, but make it so players are literally stepping out of the cornfield onto a first-class major league field that has been transplanted in the middle of an Iowa farm. We built it, and they came.”

Come gametime, BrightView’s 12 person grounds crew, which includes eight native Iowans, is responsible for mowing, painting, and lining the field, as well as raking the base paths, grooming the infield, and changing bases between innings.

“MLB at Field of Dreams exemplifies BrightView’s passion for and commitment to helping bring grandiose ideas, improbable concepts, and even movie dreams to life,” said Andrew Masterman, BrightView President and Chief Executive Officer. “Each project we work on with Major League Baseball is unique and presents its own challenges, but Murray and his crew are the best in the business and they always rise to the occasion.”

Field of Dreams Field Fast Facts

  • 100,000 square feet of sod was laid
  • 30,000 cubic yards of material was excavated
  • 4,000 tons of sand and 2,000 tons of pea gravel was installed under the new grass

 

  • 300 pounds of grass seed was used
  • 159 acres of corn, standing 10 to 12 feet tall, surround the field
  • 8 Iowans work on BrightView’s gameday grounds crew

BrightView is the nation’s leading commercial landscape company, providing a wide range of services, from design, maintenance, and snow and ice removal to tree care, golf course maintenance, sports turf, and more.

The Field of Dreams game is yet another special project in a long line of celebrated games that BrightView has assisted MLB. Following completion of this game, BrightView will again oversee field management for MLB’s Little League Classic in Williamsport, Pa., where the sports turf team has maintained historic Bowman Field since the inaugural contest was played in 2017. The company has also worked with MLB to develop, construct, and maintain fields for the Fort Bragg Game (2016), London (2019) and Japan (2019) series, and the historic exhibition game played in Havana, Cuba (2016), among other notable games.

Field of Dreams © Universal City Studios LLC. All Rights Reserved.

About BrightView

BrightView (NYSE: BV), the nation’s largest commercial landscaper, proudly designs, creates, and maintains the best landscapes on Earth and provides the most efficient and comprehensive snow and ice removal services. With a dependable service commitment, BrightView brings brilliant landscapes to life at premier properties across the United States, including business parks and corporate offices, homeowners’ associations, healthcare facilities, educational institutions, retail centers, resorts and theme parks, municipalities, golf courses, and sports venues. BrightView also serves as the Official Field Consultant to Major League Baseball. Through industry-leading best practices and sustainable solutions, BrightView is invested in taking care of our team members, engaging our clients, inspiring our communities, and preserving our planet. Visit www.BrightView.com and connect with us on Twitter, Facebook, and LinkedIn.

Source: BrightView Landscapes

David Freireich

(484) 567-7244

[email protected]

Candice Henry

(484) 567-7236

[email protected]

KEYWORDS: United States North America Pennsylvania Iowa

INDUSTRY KEYWORDS: Baseball Sports Other Construction & Property Commercial Building & Real Estate Construction & Property Landscape

MEDIA:

Logo
Logo
Photo
Photo
BrightView, the Official Field Consultant of Major League Baseball, is working with MLB to prepare the ballfield for the 2022 edition of the Field of Dreams game. (Photo: Business Wire)

Magellan Rx Management Collaborates with COEUS to Drive Adoption of Outcomes-Based Care for State Medicaid Clients Nationwide

Magellan Rx Management Collaborates with COEUS to Drive Adoption of Outcomes-Based Care for State Medicaid Clients Nationwide

FRISCO, Texas–(BUSINESS WIRE)–Magellan Rx Management, the full-service pharmacy benefit management division of Magellan Health, Inc., today announced a collaboration with COEUS HealthCare that will support the accelerated adoption of outcomes-based care and help improve patient access to lifesaving therapies, linking health outcomes to the cost of a drug and the value it provides on behalf of Magellan Rx’s state government programs.

Through this collaboration, Magellan Rx will leverage COEUS HealthCare to develop and administer VBCs on the COEBRA™ Platform, a SaaS solution designed to address the challenges associated with managing outcomes-based agreements. Data, analytics and consensus are common barriers to the implementation of value-based agreements. The COEBRA™ Platform interprets large, disparate, real-world data sets and accurately summarizes results. The demonstration of total therapeutic impact on a patient’s illness and the resulting system savings are critical to addressing the needs of unique state Medicaid populations.

“At Magellan Rx, we are deeply committed to innovation that supports the complex and evolving needs of our customers and the patients we serve. This collaboration brings the best of Magellan Rx’s Medicaid expertise coupled with COEUS HealthCare and the COEBRA™ Platform which will ultimately deliver better health outcomes for patients while also driving positive economic impact on state budgets,” said Meredith Delk, General Manager and Senior Vice President, Government Markets, Magellan Rx Management. “With spending on specialty drugs in Medicaid rising year over year coupled with far more costly drugs coming to market, we must establish new, measurable ways to lower costs and improve patient care. We offer more than 40 years of Medicaid focused expertise, including extensive knowledge of the trends driving state pharmacy spend. By leveraging the COEBRA™ platform, we can further advance the adoption and management of value-based care on behalf of our government and state clients.”

With this collaboration, Magellan Rx will offer MRx Value Plus, a value-based contracting product that provides state Medicaid programs across the country with another tool to manage overall healthcare costs and quality by paying for drugs that are efficacious. MRx Value Plus centers around improving patient care by linking outcomes with cost effectiveness. If health outcomes are not realized, the manufacturer will refund a portion of the cost of the drug back to the state, shifting the focus from volume to value.

“With the publication of the Value-Based Purchasing (VBP) final rule by CMS, state Medicaid programs, commercial payers and manufacturers are set to benefit from changes in best price reporting on utilization associated with outcomes-based contracting,” said Doug Brown, Senior Vice President, Value and Access at COEUS. “What’s really exciting for states is their ability to augment existing volume-based payment methodologies in a way that better aligns drug coverage and reimbursement with validated clinical outcomes. As the pipeline of gene and cell therapy drugs grows, new ways of paying for them are emerging and will become critical for their successful adoption and appropriate use within the patient populations they are designed to help.”

Launched with its first client in 2019, the HIPAA compliant COEBRA™ Platform intakes pharmacy claims, medical claims, invoice data, and patient-reported outcomes into a multi-variable analytical intelligence platform powered to showcase any VBC outcome. Once collected and analyzed, outcomes-based contract metrics determine how the therapy performs in the real world in order to demonstrate effectiveness and support market value with payers, plans, PBMs and, most importantly, the patients they serve.

About COEUS HealthCare:Established in 2019, COEUS HealthCare is the division of COEUS Holdings responsible for the development of the SaaS solution, COEBRA™, a value-based, outcomes and warranty adjudication platform. COEBRA™ supports the collection and secure housing of data that allows disparate data sources to be combined and analyzed to better demonstrate total therapeutic impact on a patient’s illness. With today’s innovative and breakthrough medicines, there may not always be a clinical marker available to measure the value of the therapy. The COEBRA™ platform offers a composite view of the therapeutic impact to both payers and manufacturers by incorporating metrics from claims data, electronic medical records, supply chain, patients and providers and wearables. For more information, visit www.coeus-healthcare.com.

About Magellan Rx Management: Magellan Rx Management, a division of Magellan Health, Inc., is shaping the future of pharmacy. As a next-generation pharmacy organization, we deliver meaningful solutions to the people we serve. As pioneers in specialty drug management, industry leaders in Medicaid pharmacy programs and disruptors in pharmacy benefit management, we partner with our customers and members to deliver a best-in-class healthcare experience.

About Magellan Health:Magellan Health, Inc. is a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare. Magellan supports innovative ways of accessing better health through technology, while remaining focused on the critical personal relationships that are necessary to achieve a healthy, vibrant life. Magellan’s customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators. For more information, visit MagellanHealth.com.

(MGLN-GEN)

Media Contact: Lilly Ackley, [email protected], (860) 507-1923

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Professional Services Health Other Professional Services Other Health General Health Pharmaceutical

MEDIA:

Logo
Logo

CorVel Announces Revenues and Earnings

FORT WORTH, Texas, Aug. 02, 2022 (GLOBE NEWSWIRE) — CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter ended June 30, 2022. Earnings per share for the quarter were $0.94, compared to $0.92 in the same quarter of the prior year. Revenues for the quarter were $176 million, an increase from $153 million in the same quarter of the previous year.

The Company’s conservative approach to business continues to support a high return on equity despite current inflation and economic dynamics. Revenue growth in the year has been strong led by CERiS, in the payment integrity space. The results achieved are a continuation of top-line growth from June quarters in the years prior, discounting the pandemic low from 2020.

During the quarter, developing and optimizing systems to enhance team member efficiency and effectiveness remained a focus. These investments result in increasingly automated and augmented workflows which increase and enhance the team’s throughput as well as the results achieved for CorVel’s partners.

About CorVel

CorVel Corporation applies technology including artificial intelligence, machine learning and natural language processing to enhance the managing of episodes of care and the related health care costs. We partner with employers, third-party administrators, insurance companies and government agencies in managing workers’ compensation and health, auto and liability services. Our diverse suite of solutions combines our integrated technologies with a human touch. CorVel’s customized services, delivered locally, are backed by a national team to support clients as well as their customers and patients.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on the Company’s current expectations, estimates and projections about the Company, management’s beliefs, and certain assumptions made by the Company, and events beyond the Company’s control, all of which are subject to change. Such forward-looking statements include, but are not limited to, statements relating to our commercial health-focused operation, improved productivity resulting from automation and augmentation across enterprise business systems, and expansion within our ancillary network. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially and adversely from those expressed in any forward-looking statement, including the risk that the impact of the COVID-19 pandemic on our business, results of operations and financial condition is greater than our initial assessment.

The risks and uncertainties referred to above include but are not limited to factors described in this press release and the Company’s filings with the Securities and Exchange Commission, including but not limited to “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2022 and the Company’s Quarterly Report on Form 10-Q for the quarters ended June 30, 2021, September 30, 2021, and December 31, 2021. The forward-looking statements in this press release speak only as of the date they are made. The Company undertakes no obligation to revise or update publicly any forward-looking statement for any reason.

CorVel Corporation

Quarterly Results – Income Statement

Quarters Ended June 30, 2022 (unaudited) and June 30, 2021 (unaudited)

Quarter Ended   June 30, 2022     June 30, 2021  
Revenues   $ 176,307,000     $ 152,620,000  
Cost of revenues     136,438,000       115,407,000  
Gross profit     39,869,000       37,213,000  
General and administrative     18,671,000       16,645,000  
Income from operations     21,198,000       20,568,000  
Income tax provision     4,507,000       3,725,000  
Net income   $ 16,691,000     $ 16,843,000  
Earnings Per Share:            
Basic   $ 0.95     $ 0.94  
Diluted   $ 0.94     $ 0.92  
Weighted Shares            
Basic     17,506,000       17,897,000  
Diluted     17,803,000       18,220,000  



CorVel Corporation

Quarterly Results – Condensed Balance Sheet

June 30, 2022 (unaudited) and March 31, 2022

    June 30, 2022     March 31, 2022  
Cash   $ 94,308,000     $ 97,504,000  
Customer deposits     74,421,000       69,781,000  
Accounts receivable, net     81,090,000       82,586,000  
Prepaid taxes and expenses     10,816,000       15,123,000  
Property, net     83,707,000       76,268,000  
Goodwill and other assets     38,887,000       38,964,000  
Right-of-use asset, net     32,448,000       35,020,000  
Total   $ 415,677,000     $ 415,246,000  
Accounts and taxes payable   $ 23,901,000     $ 14,431,000  
Accrued liabilities     157,504,000       156,939,000  
Deferred tax liability     1,345,000       1,689,000  
Long-term lease liabilities     27,299,000       29,792,000  
Paid-in capital     204,842,000       201,612,000  
Treasury stock     (681,208,000 )     (654,520,000 )
Retained earnings     681,994,000       665,303,000  
Total   $ 415,677,000     $ 415,246,000  

Contact: Melissa Storan
Phone: 949-851-1473
www.corvel.com



Clearway Energy, Inc. Reports Second Quarter 2022 Financial Results

  • Signed binding agreement to acquire a 413 MW wind portfolio
  • Executed new Resource Adequacy contracts for Marsh Landing; plant now fully contracted through 2026
  • Reaffirming 2022 financial guidance and raising pro forma CAFD outlook
  • TotalEnergies entered into an agreement to acquire a 50% interest in Clearway’s sponsor from Global Infrastructure Partners
  • Increasing the quarterly dividend by 2%
    to $0.3604
    p
    er share in the third quarter of 20
    22, or $1.442 p
    er share annualized
  • Continue to target annual dividend per share growth in the upper range of 5% to 8% through 2026

PRINCETON, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) — Clearway Energy, Inc. (NYSE: CWEN, CWEN.A) today reported second quarter 2022 financial results, including Net Income of $1,149 million, Adjusted EBITDA of $366 million, Cash from Operating Activities of $186 million, and Cash Available for Distribution (CAFD) of $176 million.

“Clearway’s year to date financial performance is materially in-line with expectations as 2nd quarter consolidated CAFD results were within the Company’s sensitivity range,” said Christopher Sotos, Clearway Energy, Inc.’s President and Chief Executive Officer. “With the binding agreement to acquire the Capistrano wind portfolio, the Company has now committed to, or has line of sight on, the future deployment of over 55% of the $750 million of excess proceeds from the Thermal sale and remains on track to achieve its long-term growth objectives, including the ability to deliver at the upper range of its dividend growth target through 2026.”

Adjusted EBITDA and Cash Available for Distribution used in this press release are non-GAAP measures and are explained in greater detail under “Non-GAAP Financial Information” below.

Overview of Financial and Operating Results

Segment Results

Table 1: Net Income/(Loss)

($ millions)   Three Months Ended   Six Months Ended
Segment   6/30/22   6/30/21   6/30/22   6/30/21
Conventional     33       40       80       73  
Renewables     83       27       (36 )     (29 )
Thermal     4       6       17       10  
Corporate     1,029       (41 )     991       (98 )
Net Income/(Loss)   $ 1,149     $ 32     $ 1,052     $ (44 )




Table 2: Adjusted EBITDA

($ millions)   Three Months Ended   Six Months Ended
Segment   6/30/22   6/30/21   6/30/22   6/30/21
Conventional     85       96       183       183  
Renewables     285       257       439       360  
Thermal     5       19       23       36  
Corporate     (9 )     (7 )     (19 )     (16 )
Adjusted EBITDA   $ 366     $ 365       626     $ 563  



Table 3: Cash from Operating Activities and Cash Available for Distribution (CAFD)

    Three Months Ended   Six Months Ended
($ millions)   6/30/22   6/30/21   6/30/22   6/30/21
Cash from Operating Activities   $ 186     $ 194       279       241  
Cash Available for Distribution (CAFD)   $ 176     $ 155     $ 174     $ 140  


For the second quarter of 2022, the Company reported Net Income of $1,149 million, Adjusted EBITDA of $366 million, Cash from Operating Activities of $186 million, and CAFD of $176 million. Net Income increased versus 2021 primarily due to the one-time $1.29 billion gain from the sale of the Thermal Business. Adjusted EBITDA results in the second quarter of 2022 were higher than 2021 as the contribution from growth investments was offset by the disposition of the Thermal Business and the timing of spring outages at the Conventional segment. CAFD results during the second quarter of 2022 were higher than 2021 primarily due to growth investments and the timing of project level debt service from the Viento refinancing, which was completed in March 2022, partially offset by the disposition of the Thermal Business.


Operational Performance


Table 4: Selected Operating Results

(MWh and MWht in thousands)   Three Months Ended   Six Months Ended
    6/30/22   6/30/21   6/30/22   6/30/21
Conventional Equivalent Availability Factor1   88.3 %   97.2 %   91.8 %   90.2 %
Renewables Generation Sold (MWh)2   4,416     3,370     7,735     5,900  


In the second quarter of 2022, availability at the Conventional segment was lower than the second quarter of 2021 primarily due to the timing of spring outages versus last year and a forced outage at the El Segundo Energy Center which ended in early July of 2022. Generation in the Renewables segment during the second quarter of 2022 was 31% higher than the second quarter of 2021 primarily due to the contribution of growth investments.

________________________
1 Excludes unconsolidated projects
2 Generation sold excludes MWh that are reimbursable for economic curtailment; volumes do not include the MWh generated/sold by the Company’s equity method investments



Liquidity and Capital Resources

Table 5: Liquidity

($ millions)   6/30/2022   12/31/2021
Cash and Cash Equivalents:        
Clearway Energy, Inc. and Clearway Energy LLC, excluding subsidiaries   $ 820     $ 33  
Subsidiaries     135       146  
Restricted Cash:        
Operating accounts     143       246  
Reserves, including debt service, distributions, performance obligations and other reserves     190       229  
Total Cash   $ 1,288     $ 654  
Revolving credit facility availability     408       167  
Total Liquidity   $ 1,696     $ 821  


Total liquidity as of June 30, 2022, was $1,696 million, which was $875 million higher than as of December 31, 2021, primarily due to the proceeds received from the sale of the Thermal Business. This was partially offset by the repayment of $305 million in outstanding borrowings under the Company’s revolving credit facility and the $335 million under the Bridge Loan Agreement.

As of June 30, 2022, the Company’s liquidity included $333 million of restricted cash. Restricted cash consists primarily of funds to satisfy the requirements of certain debt arrangements and funds held within the Company’s projects that are restricted in their use. As of June 30, 2022, these restricted funds were comprised of $143 million designated to fund operating expenses, approximately $42 million designated for current debt service payments, and $122 million of reserves for debt service, performance obligations and other items including capital expenditures. The remaining $26 million is held in distribution reserve accounts.

Potential future sources of liquidity include excess operating cash flow, availability under the revolving credit facility, asset dispositions, and, subject to market conditions, new corporate debt and equity financings.

Divestitures


Thermal Disposition

On May 1, 2022, the Company completed the sale of 100% of its interests in the Thermal Business to KKR for net proceeds of approximately $1.46 billion, inclusive of working capital adjustments, which excludes approximately $18 million in transaction expenses that were incurred in connection with the disposition. The Thermal Disposition resulted in a gain of $1.29 billion. The proceeds from the sale were utilized to repay temporary cash borrowings including $305 million of outstanding borrowings under the Company’s revolving credit facility and the $335 million under the Bridge Loan Agreement. The remaining proceeds were invested in short-term investments classified as cash and cash equivalents on the Company’s consolidated balance sheet as of June 30, 2022.

Growth Investments and Strategic Announcements


Resource Adequacy Agreements at Marsh Landing

In July 2022, the Company contracted with several load serving entities to sell the remaining 20% of Marsh Landing’s available capacity commencing in May 2023. The agreements are for approximately three and a half years. Marsh Landing’s capacity is now 100% contracted for a weighted average contract tenor of approximately four years commencing in May 2023 at terms sufficient to maintain project level CAFD in-line with current expectations.


Binding Agreement to Acquire a 413 MW Wind Portfolio

On June 23, 2022, the Company entered into a binding agreement to acquire a portfolio of operating wind projects from Capistrano Wind Partners, LLC (“Capistrano Portfolio”) for, subject to closing adjustments, cash consideration of $255 million, plus the assumption of approximately $160 million of non-recourse debt. The Capistrano Portfolio consists of five utility-scale wind projects representing 413 MW of capacity located in Texas, Nebraska, and Wyoming that achieved commercial operations between 2008 to 2012. The assets within the portfolio sell power under power purchase agreements with investment-grade counterparties that have a weighted average remaining contract duration of approximately 10 years. Concurrent with the acquisition, the Company has also entered into a Development Agreement with Clearway Energy Group (“Clearway Group”), whereby Clearway Group will pay $10 million to the Company to partially fund the acquisition of the Capistrano Portfolio for an exclusive right to develop, construct, and repower the projects in the Capistrano Portfolio (“Rights Fee”)3.

The Company expects its total long-term corporate capital commitment for the acquisition to be approximately $110-130 million4 and is estimated to provide incremental annual levered asset CAFD on a five-year average basis of approximately $12-14 million beginning January 1, 2023. The Company expects the transaction to close in the second half of 2022.

________________________
3 The Development Agreement is subject to certain terms and conditions. Upon the first repowering, if any, the Company will reimburse Clearway Group for the Rights Fee at a pre-agreed internal rate of return
4 Subject to customary working capital and other closing adjustments; the long-term corporate capital commitment factors in estimated closing adjustments, proceeds from the Rights Fee, and new non-recourse debt




TotalEnergies Agreement to Acquire a 50% Interest in Clearway Group


On May 25, 2022, the Company, and its renewable development partner and parent company, Clearway Group, announced that Global Infrastructure Partners (GIP) had entered into an agreement whereby TotalEnergies will acquire half of GIP’s interest in Clearway Group. In consideration, GIP will receive $1.6 billion cash consideration (subject to purchase price adjustments) and an approximately 50% interest in the TotalEnergies subsidiary that holds its 51% ownership in SunPower Corporation (NASDAQ: SPWR).

TotalEnergies is expected to enhance growth prospects for the Clearway enterprise by providing (i) a right of first offer on its U.S. onshore renewable assets to the Company and (ii) access to TotalEnergies’ power marketing capabilities and corporate relationships to optimize the commercial value of Clearway’s development and operating projects.

The closing of the transaction is subject to customary conditions, including regulatory approvals, and is expected to close in the second half of 2022.

Financing Update


Bridge Loan Agreement

On November 30, 2021, Clearway Energy Operating LLC entered into a senior secured bridge credit agreement, or the Bridge Loan Agreement, that provided for a term loan facility with an aggregate principal amount of $335 million. The borrowings under the Bridge Loan Facility were used to acquire the Utah Solar Portfolio on December 1, 2021. On May 3, 2022, the Company used proceeds from the disposition of the Thermal Business to repay the outstanding principal of $335 million.

Quarterly Dividend

On August 1, 2022, Clearway Energy, Inc.’s Board of Directors declared a quarterly dividend on Class A and Class C common stock of $0.3604 per share payable on September 15, 2022, to stockholders of record as of September 1, 2022.

For 2022, the Company anticipates that, due to the sale of the Thermal Business, it may have positive current year earnings and profits. As a result, a portion of any dividends paid to holders of Class A and Class C common stock in 2022 may be treated as taxable dividends for U.S. federal income tax purposes. Such portion of the dividends that could be treated as taxable will depend upon a number of factors, including, but not limited to, the amount of actual gain from the Thermal business sale, overall business performance, and other business activity during the year.

Seasonality

Clearway Energy, Inc.’s quarterly operating results are impacted by seasonal factors, as well as weather variability which can impact renewable energy resource. Most of the Company’s revenues are generated from the months of May through September, as contracted pricing and renewable resources are at their highest levels in the Company’s portfolio. Factors driving the fluctuation in Net Income, Adjusted EBITDA, Cash from Operating Activities, and CAFD include the following:

  • Higher summer capacity prices from conventional assets;
  • Higher solar insolation during the summer months;
  • Higher wind resources during the spring and summer months;
  • Debt service payments which are made either quarterly or semi-annually;
  • Timing of maintenance capital expenditures and the impact of both unforced and forced outages; and
  • Timing of distributions from unconsolidated affiliates

The Company takes into consideration the timing of these factors to ensure sufficient funds are available for distributions and operating activities on a quarterly basis.

Financial Guidance and Pro Forma CAFD Outlook

The Company is reaffirming its 2022 full year CAFD guidance of $365 million. The Company’s 2022 financial guidance factors in the contribution of committed growth investments based on current expected closing timelines and the closing of Thermal disposition on May 1, 2022. 2022 CAFD guidance does not factor in the timing of when CAFD is realized from new growth investments pursuant to 5-year averages beyond 2022.

With the effects above, the timing of CAFD realization pursuant to 5-year averages, the acquisition of the Capistrano Portfolio, and asset CAFD across all segments being materially in-line with current profiles, the Company is increasing its pro forma CAFD outlook expectations to approximately $400 million from $385 million.

Financial guidance and the pro forma CAFD outlook continue to be based on median renewable energy production estimates for the full year.

Earnings Conference Call

On August 2, 2022, Clearway Energy, Inc. will host a conference call at 8:00 a.m. Eastern to discuss these results. Investors, the news media and others may access the live webcast of the conference call and accompanying presentation materials by logging on to Clearway Energy, Inc.’s website at http://www.clearwayenergy.com and clicking on “Presentations & Webcasts” under “Investor Relations.”

About Clearway Energy, Inc.

Clearway Energy, Inc. is one of the largest renewable energy owners in the US with over 5,000 net MW of installed wind and solar generation projects. The Company’s over 7,500 net MW of assets also include approximately 2,500 net MW of environmentally-sound, highly efficient natural gas generation facilities. Through this environmentally-sound diversified and primarily contracted portfolio, Clearway Energy endeavors to provide its investors with stable and growing dividend income. Clearway Energy’s Class C and Class A common stock are traded on the New York Stock Exchange under the symbols CWEN and CWEN.A, respectively. Clearway Energy, Inc. is sponsored by its controlling investor, Global Infrastructure Partners.

Safe Harbor Disclosure

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are subject to certain risks, uncertainties and assumptions, and typically can be identified by the use of words such as “expect,” “estimate,” “target,” “anticipate,” “forecast,” “plan,” “outlook,” “believe” and similar terms. Such forward-looking statements include, but are not limited to, statements regarding, the Company’s dividend expectations and its operations, its facilities and its financial results, impacts related to COVID-19 (including any variant of the virus) or any other pandemic, statements regarding the anticipated consummation of the transactions described above, the anticipated benefits, opportunities, and results with respect to the transactions, including the Company’s anticipated future relationship and arrangements with Global Infrastructure Partners, TotalEnergies and Clearway Energy Group, as well as the Company’s Net Income, Adjusted EBITDA, Cash from Operating Activities, Cash Available for Distribution, the Company’s future revenues, income, indebtedness, capital structure, strategy, plans, expectations, objectives, projected financial performance and/or business results and other future events, and views of economic and market conditions.

Although Clearway Energy, Inc. believes that the expectations are reasonable, it can give no assurance that these expectations will prove to be correct, and actual results may vary materially. Factors that could cause actual results to differ materially from those contemplated above include, among others, the Company’s ability to maintain and grow its quarterly dividend, impacts related to COVID-19 (including any variant of the virus) or any other pandemic, risks relating to the Company’s relationships with its sponsors, the failure to identify, execute or successfully implement acquisitions or dispositions (including receipt of third party consents and regulatory approvals), the Company’s ability to acquire assets from its sponsors, the Company’s ability to raise additional capital due to its indebtedness, corporate structure, market conditions or otherwise, hazards customary in the power industry, weather conditions, including wind and solar performance, the Company’s ability to operate its businesses efficiently, manage maintenance capital expenditures and costs effectively, and generate earnings and cash flows from its asset-based businesses in relation to its debt and other obligations, the willingness and ability of counterparties to the Company’s offtake agreements to fulfill their obligations under such agreements, the Company’s ability to enter into new contracts as existing contracts expire, changes in government regulations, operating and financial restrictions placed on the Company that are contained in the project-level debt facilities and other agreements of the Company and its subsidiaries, cyber terrorism and inadequate cybersecurity and the Company’s ability to borrow additional funds and access capital markets. Furthermore, any dividends are subject to available capital, market conditions, and compliance with associated laws and regulations.

Clearway Energy, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The Cash Available for Distribution are estimates as of today’s date, August 2, 2022, and are based on assumptions believed to be reasonable as of this date. Clearway Energy, Inc. expressly disclaims any current intention to update such guidance. The foregoing review of factors that could cause Clearway Energy, Inc.’s actual results to differ materially from those contemplated in the forward-looking statements included in this news release should be considered in connection with information regarding risks and uncertainties that may affect Clearway Energy, Inc.’s future results included in Clearway Energy, Inc.’s filings with the Securities and Exchange Commission at www.sec.gov. In addition, Clearway Energy, Inc. makes available free of charge at www.clearwayenergy.com, copies of materials it files with, or furnishes to, the Securities and Exchange Commission.

Contacts:

  Investors:

Akil Marsh 
[email protected] 
609-608-1500
Media:

Zadie Oleksiw
[email protected]
202-836-5754





CLEARWAY ENERGY, INC.

CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

  Three months ended
June 30,
  Six months ended
June 30,
(In millions, except per share amounts)   2022       2021       2022       2021  
Operating Revenues              
Total operating revenues $ 368     $ 380     $ 582     $ 617  
Operating Costs and Expenses              
Cost of operations, exclusive of depreciation, amortization and accretion shown separately below   112       107       240       217  
Depreciation, amortization and accretion   126       128       250       256  
General and administrative   11       10       23       20  
Transaction and integration costs   3       1       5       3  
Development costs   1       1       2       2  
Total operating costs and expenses   253       247       520       498  
Gain on sale of business   1,291             1,291        
Operating Income   1,406       133       1,353       119  
Other Income (Expense)              
Equity in earnings of unconsolidated affiliates   10       8       14       12  
Other income, net   5       1       5       2  
Loss on debt extinguishment               (2 )     (42 )
Interest expense   (47 )     (103 )     (94 )     (148 )
Total other expense, net   (32 )     (94 )     (77 )     (176 )
Income (Loss) Before Income Taxes   1,374       39       1,276       (57 )
Income tax expense (benefit)   225       7       224       (13 )
Net Income (Loss)   1,149       32       1,052       (44 )
Less: Income (loss) attributable to noncontrolling interests and redeemable noncontrolling interests   579       (3 )     514       (82 )
Net Income Attributable to Clearway Energy, Inc. $ 570     $ 35     $ 538     $ 38  
Earnings Per Share Attributable to Clearway Energy, Inc. Class A and Class C Common Stockholders              
Weighted average number of Class A common shares outstanding – basic and diluted   35       35       35       35  
Weighted average number of Class C common shares outstanding – basic and diluted   82       82       82       82  
Earnings per Weighted Average Class A and Class C Common Share – Basic and Diluted $ 4.89     $ 0.30     $ 4.62     $ 0.32  
Dividends Per Class A Common Share $ 0.3536     $ 0.3290     $ 0.7004     $ 0.6530  
Dividends Per Class C Common Share $ 0.3536     $ 0.3290     $ 0.7004     $ 0.6530  





CLEARWAY ENERGY, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

  Three months ended
June 30,
  Six months ended
June 30,

(In millions)
  2022       2021       2022       2021  
Net Income (Loss) $ 1,149     $ 32     $ 1,052     $ (44 )
Other Comprehensive Income              
Unrealized gain on derivatives, net of income tax expense of, $1, $— ,$3 and $2   6             20       11  
Other comprehensive income   6             20       11  
Comprehensive Income (Loss)   1,155       32       1,072       (33 )
Less: Comprehensive income (loss) attributable to noncontrolling interests and redeemable noncontrolling interests   583       (3 )     526       (75 )
Comprehensive Income Attributable to Clearway Energy, Inc. $ 572     $ 35     $ 546     $ 42  





CLEARWAY ENERGY, INC.

CONSOLIDATED BALANCE SHEETS

(In millions, except shares) June 30, 2022   December 31, 2021
ASSETS (Unaudited)    
Current Assets      
Cash and cash equivalents $ 955     $ 179  
Restricted cash   333       475  
Accounts receivable — trade   222       144  
Accounts receivable — affiliates   2        
Inventory   39       37  
Derivative instruments   9        
Current assets held-for-sale         631  
Prepayments and other current assets   75       65  
Total current assets   1,635       1,531  
Property, plant and equipment, net   7,545       7,650  
Other Assets      
Equity investments in affiliates   375       381  
Intangible assets for power purchase agreements, net   2,340       2,419  
Other intangible assets, net   79       80  
Derivative instruments   35       6  
Deferred income taxes         95  
Right-of-use assets, net   510       550  
Other non-current assets   129       101  
Total other assets   3,468       3,632  
Total Assets $ 12,648     $ 12,813  
LIABILITIES AND STOCKHOLDERS’ EQUITY      
Current Liabilities      
Current portion of long-term debt $ 457     $ 772  
Accounts payable — trade   59       74  
Accounts payable — affiliates   16       107  
Derivative instruments   75       46  
Accrued interest expense   57       54  
Current liabilities held-for-sale         494  
Accrued expenses and other current liabilities   85       84  
Total current liabilities   749       1,631  
Other Liabilities      
Long-term debt   6,605       6,939  
Deferred income taxes   110       13  
Derivative instruments   280       196  
Long-term lease liabilities   527       561  
Other non-current liabilities   184       173  
Total other liabilities   7,706       7,882  
Total Liabilities   8,455       9,513  
Redeemable noncontrolling interest in subsidiaries   4        
Commitments and Contingencies      
Stockholders’ Equity      
Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued          
Class A, Class B, Class C and Class D common stock, $0.01 par value; 3,000,000,000 shares authorized (Class A 500,000,000, Class B 500,000,000, Class C 1,000,000,000, Class D 1,000,000,000); 202,273,531 shares issued and outstanding (Class A 34,599,645, Class B 42,738,750, Class C 82,196,386, Class D 42,738,750) at June 30, 2022 and 201,856,166 shares issued and outstanding (Class A 34,599,645, Class B 42,738,750, Class C 81,779,021, Class D 42,738,750) at December 31, 2021   1       1  
Additional paid-in capital   1,785       1,872  
Retained earnings (accumulated deficit)   505       (33 )
Accumulated other comprehensive income (loss)   2       (6 )
Noncontrolling interest   1,896       1,466  
Total Stockholders’ Equity   4,189       3,300  
Total Liabilities and Stockholders’ Equity $ 12,648     $ 12,813  





CLEARWAY ENERGY, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

  Six months ended June 30,
(In millions)   2022       2021  
Cash Flows from Operating Activities      
Net Income (Loss) $ 1,052     $ (44 )
Adjustments to reconcile net income (loss) to net cash provided by operating activities:      
Equity in earnings of unconsolidated affiliates   (14 )     (12 )
Distributions from unconsolidated affiliates   17       16  
Depreciation, amortization and accretion   250       256  
Amortization of financing costs and debt discounts   7       7  
Amortization of intangibles   82       70  
Loss on debt extinguishment   2       42  
Gain on sale of business   (1,291 )      
Reduction in carrying amount of right-of-use assets   7       5  
Changes in deferred income taxes   197       (13 )
Changes in derivative instruments   92       20  
Cash used in changes in other working capital:      
Changes in prepaid and accrued liabilities for tolling agreements   (74 )     (76 )
Changes in other working capital   (48 )     (30 )
Net Cash Provided by Operating Activities   279       241  
Cash Flows from Investing Activities      
Acquisitions, net of cash acquired         (211 )
Acquisition of Drop Down Assets   (51 )     (132 )
Capital expenditures   (81 )     (93 )
Asset purchase from affiliate         (21 )
Return of investment from unconsolidated affiliates   6       20  
Cash receipts from notes receivable         4  
Proceeds from sale of business   1,457        
Other         13  
Net Cash Provided by (Used in) Investing Activities   1,331       (420 )
Cash Flows from Financing Activities      
(Distributions to) contributions from noncontrolling interests   (7 )     265  
Payments of dividends and distributions   (141 )     (132 )
Distributions to CEG of escrowed amounts   (64 )      
Proceeds from the revolving credit facility   80       300  
Payments for the revolving credit facility   (325 )     (233 )
Proceeds from the issuance of long-term debt   214       1,016  
Payments of debt issuance costs   (4 )     (13 )
Payments for short-term and long-term debt   (722 )     (1,028 )
Other   (7 )     9  
Net Cash (Used in) Provided by Financing Activities   (976 )     184  
Net Increase in Cash, Cash Equivalents and Restricted Cash   634       5  
Cash, Cash Equivalents and Restricted Cash at beginning of period   654       465  
Cash, Cash Equivalents and Restricted Cash at end of period $ 1,288     $ 470  





CLEARWAY ENERGY, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the Six Months Ended June 30, 2022

(Unaudited)

(In millions) Preferred
Stock
  Common
Stock
  Additional

Paid-In

Capital
  Accumulated
Deficit
  Accumulated

Other

Comprehensive
Loss
  Noncontrolling

Interest
  Total

Stockholders’

Equity
Balances at December 31, 2021 $     $ 1     $ 1,872     $ (33 )   $ (6 )   $ 1,466     $ 3,300  
Net loss                     (32 )           (67 )     (99 )
Unrealized gain on derivatives, net of tax                           6       8       14  
Distributions to CEG, net of contributions, cash                                 (3 )     (3 )
Contributions from noncontrolling interests, net of distributions, cash                                 28       28  
Mesquite Sky Drop Down               (1 )                 (7 )     (8 )
Black Rock Drop Down                                 1       1  
Mililani I Drop Down               (11 )                 (19 )     (30 )
Non-cash adjustments for change in tax basis               8                         8  
Stock based compensation               (2 )                       (2 )
Common stock dividends and distributions to CEG unit holders               (40 )                 (30 )     (70 )
Balances at March 31, 2022 $     $ 1     $ 1,826     $ (65 )   $     $ 1,377     $ 3,139  
Net income                     570             575       1,145  
Unrealized gain on derivatives, net of tax                           2       4       6  
Distributions to CEG, net of contributions, cash                                 (20 )     (20 )
Distributions to noncontrolling interests, net of contributions, cash                                 (10 )     (10 )
Non-cash adjustments for change in tax basis               (1 )                       (1 )
Stock based compensation               1                         1  
Common stock dividends and distributions to CEG unit holders               (41 )                 (30 )     (71 )
Balances at June 30, 2022 $     $ 1     $ 1,785     $ 505     $ 2     $ 1,896     $ 4,189  





CLEARWAY ENERGY, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the Six Months Ended June 30, 2021

(Unaudited)

(In millions) Preferred
Stock
  Common
Stock
  Additional

Paid-In

Capital
  Accumulated
Deficit
  Accumulated

Other

Comprehensive
Loss
  Noncontrolling

Interest
  Total

Stockholders’

Equity
Contributions from CEG, non-cash                                 27       27  
Contributions from CEG, cash                                 103       103  
Contributions from noncontrolling interests, net of distributions, cash                                 126       126  
Net proceeds from the issuance of common stock under the ATM Program                                        
Distributions to tax equity investors, non-cash                                        
Agua Caliente acquisition                                 273       273  
Stock based compensation                                        
Common stock dividends and distributions to CEG unit holders               (38 )                 (28 )     (66 )
Balances at March 31, 2021 $     $ 1     $ 1,886     $ (81 )   $ (10 )   $ 1,199     $ 2,995  
Net income (loss)                     35             (4 )     31  
Unrealized gain (loss) on derivatives, net of tax                           1       (1 )      
Contributions from CEG, non-cash                                 3       3  
Contributions from CEG, cash                                 1       1  
Contributions from noncontrolling interests, net of distributions, cash                                 38       38  
Rattlesnake Drop Down                                 1       1  
Stock-based compensation               1                         1  
Non-cash adjustment for change in tax basis               (1 )                       (1 )
Common stock dividends and distributions to CEG unit holders               (38 )                 (28 )     (66 )
Balances at June 30, 2021 $     $ 1     $ 1,848     $ (46 )   $ (9 )   $ 1,209     $ 3,003  






Appendix Table A-1: Three Months Ended June 30, 2022, Segment Adjusted EBITDA Reconciliation

The following table summarizes the calculation of Adjusted EBITDA and provides a reconciliation to Net Income/(Loss):

($ in millions)   Conventional   Renewables   Thermal   Corporate   Total
Net Income (Loss)   $ 33     $ 83     $ 4     $ 1,029     $ 1,149  
Plus:                    
Income Tax Expense                       225       225  
Interest Expense, net     10       10       1       24       45  
Depreciation, Amortization, and ARO     33       93                   126  
Contract Amortization     6       35                   41  
Mark to Market (MtM) Losses on economic hedges           52                   52  
Transaction and integration costs                       3       3  
Other non-recurring                       (1,291 )     (1,291 )
Adjustments to reflect CWEN’s pro-rata share of Adjusted EBITDA from Unconsolidated Affiliates     3       12                   15  
Non-Cash Equity Compensation                       1       1  
Adjusted EBITDA   $         85             $         285             $         5             $         (9 )   $         366          




Appendix Table A-2: Three Months Ended June 30, 2021, Segment Adjusted EBITDA Reconciliation


The following table summarizes the calculation of Adjusted EBITDA and provides a reconciliation to Net Income/(Loss):

($ in millions)   Conventional   Renewables   Thermal   Corporate   Total
Net Income (Loss)   $ 40     $ 27     $ 6     $ (41 )   $ 32  
Plus:                    
Income Tax Expense                       7       7  
Interest Expense, net     16       58       4       25       103  
Depreciation, Amortization, and ARO     31       89       8             128  
Contract Amortization     6       30       1             37  
Mark to Market (MtM) Losses on economic hedges           31                   31  
Transaction and integration costs                       1       1  
Other non-recurring           1                   1  
Adjustments to reflect CWEN’s pro-rata share of Adjusted EBITDA from Unconsolidated Affiliates     3       21                   24  
Non-Cash Equity Compensation                       1       1  
Adjusted EBITDA   $ 96     $ 257     $ 19     $ (7 )   $ 365  




Appendix Table A-3: Six Months Ended June 30, 2022, Segment Adjusted EBITDA Reconciliation

The following table summarizes the calculation of Adjusted EBITDA and provides a reconciliation to Net Income/(Loss):

    Conventional   Renewables   Thermal   Corporate   Total
Net Income (Loss)   $ 80     $ (36 )   $ 17     $ 991     $ 1,052  
Plus:                    
Income Tax Expense                       224       224  
Interest Expense, net     18       18       6       50       92  
Depreciation, Amortization, and ARO     66       184                   250  
Contract Amortization     12       71                   83  
Loss on Debt Extinguishment           2                   2  
Mark to Market (MtM) Losses on Economic Hedges           178                   178  
Transaction and Integration costs                       5       5  
Other Non-recurring     1                   (1,291 )     (1,290 )
Adjustments to reflect CWEN’s pro-rata share of Adjusted EBITDA from Unconsolidated Affiliates     6       22                   28  
Non-Cash Equity Compensation                       2       2  
Adjusted EBITDA   $ 183     $ 439     $ 23     $ (19 )   $ 626  




Appendix Table A-4: Six Months Ended June 30, 2021, Segment Adjusted EBITDA Reconciliation

The following table summarizes the calculation of Adjusted EBITDA and provides a reconciliation to Net Income/(Loss):

    Conventional   Renewables   Thermal   Corporate   Total
Net Income (Loss)   $ 73     $ (29 )   $ 10     $ (98 )   $ (44 )
Plus:                    
Income Tax Benefit                       (13 )     (13 )
Interest Expense, net     27       62       9       50       148  
Depreciation, Amortization, and ARO     65       176       15             256  
Contract Amortization     12       55       2             69  
Loss on Debt Extinguishment           1             41       42  
Mark to Market (MtM) Losses
on economic hedges
          55                   55  
Transaction and Integration costs                       3       3  
Other Non-recurring           1                   1  
Adjustments to reflect CWEN’s pro-rata share of Adjusted EBITDA from Unconsolidated Affiliates     6       39                   45  
Non-Cash Equity Compensation                       1       1  
Adjusted EBITDA   $ 183     $ 360     $ 36     $ (16 )   $ 563  




Appendix Table A-5: Cash Available for Distribution Reconciliation


The following table summarizes the calculation of Cash Available for Distribution and provides a reconciliation to Cash from Operating Activities:

  Three Months Ended   Six Months Ended
($ in millions) 6/30/22   6/30/21   6/30/22   6/30/21
Adjusted EBITDA $ 366     $ 365     $ 626     $ 563  
Cash interest paid   (62 )     (72 )     (159 )     (165 )
Changes in prepaid and accrued liabilities for tolling agreements   (30 )     (32 )     (74 )     (76 )
Adjustments to reflect sale-type leases and payments for lease expenses   2             3        
Pro-rata Adjusted EBITDA from unconsolidated affiliates   (25 )     (32 )     (41 )     (57 )
Distributions from unconsolidated affiliates   6       3       17       16  
Changes in working capital and other   (71 )     (38 )     (93 )     (40 )
Cash from Operating Activities   186       194       279       241  
Changes in working capital and other   71       38       93       40  
Development Expenses5   1       1       2       2  
Return of investment from unconsolidated affiliates   3       12       6       20  
Net contributions (to)/from non-controlling interest6   (10 )     (12 )     (20 )     15  
Maintenance capital expenditures   (5 )     (6 )     (12 )     (12 )
Principal amortization of indebtedness7   (70 )     (72 )     (174 )     (166 )
Cash Available for Distribution $ 176     $ 155     $ 174     $ 140  

________________________
5 Primarily relates to Thermal Development Expenses
6 2022 excludes $50 million of contributions related to the funding of Mesquite Sky, Black Rock, and Mililani; 2021 excludes $107 million of contributions related to funding of Rattlesnake
7 2022 excludes $660 million for the repayment of the Bridge Loan Facility and revolver payments, $186 million for the refinancing of Tapestry Wind, Laredo Ridge, and Viento, and $27 million for the repayment of bridge loans in connection with Mililani; 2021 excludes $868 million total consideration for the redemption of Corporate Notes and revolver payments and $52 million in connection with Pinnacle repowering






Appendix Table A-6: Six Months Ended June 30, 2022, Sources and Uses of Liquidity

The following table summarizes the sources and uses of liquidity in 2022:

    Six Months
Ended
($ in millions)   6/30/22
Sources:    
Proceeds from sale of business     1,457  
Net cash provided by operating activities     279  
Proceeds from issuance of long-term debt     214  
Proceeds from the revolving credit facility     80  
Return of investment from unconsolidated affiliates     6  
     
Uses:    
Payments for long-term debt     (722 )
Payments for the revolving credit facility     (325 )
Payments of dividends and distributions     (141 )
Capital expenditures     (81 )
Distributions to CEG of escrowed amounts     (64 )
Acquisition of Drop Down Assets, net of cash acquired     (51 )
Other net cash outflows     (18 )
     
Change in total cash, cash equivalents, and restricted cash   $ 634  




Appendix Table A-7: Adjusted EBITDA and Cash Available for Distribution Guidance and Pro Forma Outlook

($ in millions)   2022 Full
Year
Guidance
  Prior Pro
Forma
CAFD
Outlook
  Pro Forma
CAFD
Outlook
Net Income   $ 110     $ 75     $ 100  
Income Tax Expense     20       15       20  
Interest Expense, net     445       385       395  
Depreciation, Amortization, and ARO Expense     585       530       545  
Adjustment to reflect CWEN share of Adjusted EBITDA in unconsolidated affiliates     60       45       45  
Non-Cash Equity Compensation     5       5       5  
Adjusted EBITDA     1,225       1,055       1,110  
Cash interest paid     (317 )     (285 )     (296 )
Changes in prepaid and accrued liabilities for tolling agreements     10       (5 )     (5 )
Adjustments to reflect sale-type leases and payments for lease expenses     7       6       6  
Pro-rata Adjusted EBITDA from unconsolidated affiliates     (85 )     (86 )     (86 )
Cash distributions from unconsolidated affiliates8     45       48       48  
Income Tax Payment     (2 )             —                
Cash from Operating Activities     883       733       777  
Development Expense9     3              
Net distributions to non-controlling interest10     (64 )     (67 )     (67 )
Maintenance capital expenditures     (30 )     (20 )     (23 )
Principal amortization of indebtedness     (427 )     (261 )     (287 )
Cash Available for Distribution   $ 365     $ 385     $ 400  

________________________
8 Distribution from unconsolidated affiliates can be classified as Return of Investment on Unconsolidated Affiliates when actuals are reported. This is below cash from operating activities
9 Primarily related to Thermal Development Expenses
10 Includes tax equity proceeds and distributions to tax equity partners






Appendix Table A-8: Growth Investments 5 Year Average CAFD

($ in millions)   413 MW Wind
Portfolio

5 Year Ave. 2023-2027
   
Net Income   29 – 30    
Interest Expense, net   12 – 10    
Depreciation, Amortization, and ARO Expense   13    
Adjusted EBITDA   53    
Cash interest paid   (12) – (10)    
Cash from Operating Activities   41 – 43    
Maintenance capital expenditures   (3 )  
Principal amortization of indebtedness   (26 )  
Estimated Cash Available for Distribution   12 – 14    






Non-GAAP Financial Information


EBITDA and Adjusted EBITDA

EBITDA, Adjusted EBITDA, and Cash Available for Distribution (CAFD) are non-GAAP financial measures. These measurements are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance. The presentation of non-GAAP financial measures should not be construed as an inference that Clearway Energy’s future results will be unaffected by unusual or non-recurring items.

EBITDA represents net income before interest (including loss on debt extinguishment), taxes, depreciation and amortization. EBITDA is presented because Clearway Energy considers it an important supplemental measure of its performance and believes debt and equity holders frequently use EBITDA to analyze operating performance and debt service capacity. EBITDA has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our operating results as reported under GAAP. Some of these limitations are:

  • EBITDA does not reflect cash expenditures, or future requirements for capital expenditures, or contractual commitments;
  • EBITDA does not reflect changes in, or cash requirements for, working capital needs;
  • EBITDA does not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on debt or cash income tax payments;
  • Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA does not reflect any cash requirements for such replacements; and
  • Other companies in this industry may calculate EBITDA differently than Clearway Energy does, limiting its usefulness as a comparative measure.

Because of these limitations, EBITDA should not be considered as a measure of discretionary cash available to use to invest in the growth of Clearway Energy’s business. Clearway Energy compensates for these limitations by relying primarily on our GAAP results and using EBITDA and Adjusted EBITDA only supplementally. See the statements of cash flow included in the financial statements that are a part of this news release.

Adjusted EBITDA is presented as a further supplemental measure of operating performance. Adjusted EBITDA represents EBITDA adjusted for mark-to-market gains or losses, non-cash equity compensation expense, asset write offs and impairments; and factors which we do not consider indicative of future operating performance such as transition and integration related costs. The reader is encouraged to evaluate each adjustment and the reasons Clearway Energy considers it appropriate for supplemental analysis. As an analytical tool, Adjusted EBITDA is subject to all of the limitations applicable to EBITDA. In addition, in evaluating Adjusted EBITDA, the reader should be aware that in the future Clearway Energy may incur expenses similar to the adjustments in this news release.

Management believes Adjusted EBITDA is useful to investors and other users of our financial statements in evaluating our operating performance because it provides them with an additional tool to compare business performance across companies and across periods. This measure is widely used by investors to measure a company’s operating performance without regard to items such as interest expense, taxes, depreciation and amortization, which can vary substantially from company to company depending upon accounting methods and book value of assets, capital structure and the method by which assets were acquired.

Additionally, Management believes that investors commonly adjust EBITDA information to eliminate the effect of restructuring and other expenses, which vary widely from company to company and impair comparability. As we define it, Adjusted EBITDA represents EBITDA adjusted for the effects of impairment losses, gains or losses on sales, non-cash equity compensation expense, dispositions or retirements of assets, any mark-to-market gains or losses from accounting for derivatives, adjustments to exclude gains or losses on the repurchase, modification or extinguishment of debt, and any extraordinary, unusual or non-recurring items plus adjustments to reflect the Adjusted EBITDA from our unconsolidated investments. We adjust for these items in our Adjusted EBITDA as our management believes that these items would distort their ability to efficiently view and assess our core operating trends.

In summary, our management uses Adjusted EBITDA as a measure of operating performance to assist in comparing performance from period to period on a consistent basis and to readily view operating trends, as a measure for planning and forecasting overall expectations and for evaluating actual results against such expectations, and in communications with our Board of Directors, shareholders, creditors, analysts and investors concerning our financial performance.


Cash Available for Distribution

A non-GAAP measure, Cash Available for Distribution is defined as of June 30, 2022 as Adjusted EBITDA plus cash distributions/return of investment from unconsolidated affiliates, cash receipts from notes receivable, cash distributions from noncontrolling interests, adjustments to reflect sales-type lease cash payments and payments for lease expenses, less cash distributions to noncontrolling interests, maintenance capital expenditures, pro-rata Adjusted EBITDA from unconsolidated affiliates, cash interest paid, income taxes paid, principal amortization of indebtedness, changes in prepaid and accrued capacity payments, and adjusted for development expenses. Management believes CAFD is a relevant supplemental measure of the Company’s ability to earn and distribute cash returns to investors.

We believe CAFD is useful to investors in evaluating our operating performance because securities analysts and other interested parties use such calculations as a measure of our ability to make quarterly distributions. In addition, CAFD is used by our management team for determining future acquisitions and managing our growth. The GAAP measure most directly comparable to CAFD is cash provided by operating activities.

However, CAFD has limitations as an analytical tool because it does not include changes in operating assets and liabilities and excludes the effect of certain other cash flow items, all of which could have a material effect on our financial condition and results from operations. CAFD is a non-GAAP measure and should not be considered an alternative to cash provided by operating activities or any other performance or liquidity measure determined in accordance with GAAP, nor is it indicative of funds available to fund our cash needs. In addition, our calculations of CAFD are not necessarily comparable to CAFD as calculated by other companies. Investors should not rely on these measures as a substitute for any GAAP measure, including cash provided by operating activities.